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RESUMO 
As novas substâncias psicoativas, designadas por NSP, são consideradas um fenómeno mundial constitu-
indo uma ameaça para a saúde pública. No término de 2017, mais de 670 NSP foram reportadas pelo Obser-
vatório Europeu da Droga e da Toxicodepência (European Monitoring Centre for Drugs and Drug Addition, 
EMCDDA).  
O conceito NSP pode induzir em erro, dado que o termo “novas” pode levar à conclusão que se trata de 
substâncias recentemente introduzidas no mercado, contudo muitas delas foram desenvolvidas há mais de 40 
anos por investigadores tendo em vista, normalmente, o desenvolvimento de novos fármacos. É o caso de John 
Huffman que pretendeu estudar as interações dos recetores canabinóides, de modo a testar os efeitos da canábis 
no cérebro humano. Estes compostos pretendem mimetizar os efeitos produzidos por substâncias psicoativas 
(cocaína, anfetaminas, ecstasy, entre outras), que se encontram sob controlo internacional, tendo um grande 
impacto nos seus consumidores. O que define as NSP? Segundo o Gabinete das Nações Unidas contra a Droga 
e o Crime (United Nations Office on Drugs and Crime, UNODC), estas são descritas como “novos estupefa-
cientes ou substâncias psicotrópicas, na forma pura ou em preparação, que não são controladas pelas conven-
ções das Nações Unidas referentes aos estupefacientes (1961) e psicotrópicos (1971), mas que podem repre-
sentar um risco à saúde pública”. As NSP são caracterizadas por pequenas modificações na estrutura química 
de substâncias (normalmente ilícitas), a substituição de apenas um átomo pode contribuir para um efeito mais 
poderoso, permitindo também contornar a legislação. Estas substâncias podem ser facilmente sintetizadas por 
qualquer pessoa que detenha conhecimentos em química e os laboratórios clandestinos onde a produção toma 
lugar situam-se predominantemente na China e em menor escala na Índia. A Internet é considerada o maior 
mercado de proliferação das NSP. Estas substâncias podem ser adquiridas nas chamadas “smartshops” como 
“bath salts” e “research chemicals” ou por “street dealers” que as obtêm em mercados online e depois são 
vendidas em discotecas, festivais de música e escolas, podendo ser designadas “party pills”. É de salientar que, 
estes produtos são geralmente vendidos, contendo nos rótulos a descrição “não adequado para consumo hu-
mano”, como uma estratégia de contornar as leis nacionais e internacionais. Os efeitos associados ao seu con-
sumo, podem ser diversos e por vezes imprevisíveis. Podendo estes, variar entre efeitos estimulantes, alucino-
génios e analgésicos. O consumo de NSP tem levado a intoxicações severas, bem como casos fatais.  
O surgimento destes compostos, sob marcas e embalagens apelativas, estimula especialmente a curiosidade 
da geração mais jovem devido à sua acessibilidade e anonimato. De notar que, o ritmo acelerado com que as 
NSP aparecem nos mercados de drogas torna complicado o seu controlo. Quando uma substância chama a 
atenção das autoridades e, acaba finalmente por ser inserida na lista de substâncias controladas, rapidamente 
uma nova toma a sua posição, com o intuito de substituir aquela que foi banida do mercado.  
A identificação destas substâncias revela-se desafiante para os analistas que estão dispostos em encontrar 
uma resposta eficaz para os casos que surgem, isto deve-se sobretudo às diferenças estruturais e à ausência de 
padrões de referência. De modo a enfrentar estas questões, um grupo de investigadores Dinamarqueses tiveram 
a ideia de desenvolver uma base de dados que compreendesse novas substâncias psicoativas como também 
compostos relacionados reportados por laboratórios de todo o mundo. Assim, o mesmo composto pode conter 
mais do que uma entrada, o que de certo modo contribui para a sua validação, podendo desta forma certificar-
se que a informação fornecida é coerente. Atente-se que esta base de dados contempla elementos que são de 
cariz tanto experimental como não-experimental. Nesse sentido, esta tese consistiu em melhorar e testar esta 
biblioteca online universal (HighResNPS) destinada às NSP, quando os padrões de referência não se encon-
tram disponíveis, utilizando a cromatografia líquida de ultra eficiência acoplada à espectrometria de tempo-
de-voo (ultra-high-performance liquid chromatography quadrupole time-of-flight mass spectrometry, 
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UHPLC-QTOF-MS). O presente trabalho compreendeu duas partes fundamentais: a biblioteca e o método de 
screening. Relativamente à primeira, foi necessário assegurar que a informação apresentada no HighResNPS 
estava correta, em termos de iões fragmento, nomes IUPAC, classes de drogas, entre outros parâmetros. Graças 
à inclusão de duas features na base de dados, foi possível assinalar e corrigir 290 erros associados à massa do 
ião precursor e iões fragmento, encontrar a fórmula molecular em falta para alguns dos fragmentos e retificar 
61 nomes IUPAC. É importante ter em consideração, que através do nome IUPAC pode ser gerado o In-
ChIKey, que é um parâmetro de relevância máxima, visto que é característico de um único composto, permi-
tindo facilmente a sua identificação. Além disso, pode ser útil para proceder a uma pesquisa na Internet, isto 
é, noutras bases de dados online. Note-se, que as substâncias podem apresentar diferentes designações, do 
mesmo modo, os nomes IUPAC também podem sofrer ligeiras variações, pelo que o InChIKey é crucial para 
reconhecer a identidade do composto em questão. Verificou-se que nem sempre, foi possível, encontrar o nome 
IUPAC e consequentemente o InChIKey, o que pode ser crítico especialmente quando isómeros posicionais 
estão presentes. 
O constante aparecimento de duas classes específicas de NSP requereu uma especial atenção. Duas sub-
bibliotecas foram criadas, a primeira contendo 51 análogos do fentanil e a segunda, 215 canabinóides sintéti-
cos. Por forma, a que fornecessem uma visão geral quanto aos padrões de fragmentação, sendo estes posteri-
ormente comparados com os resultados presentes na base de dados. Em geral, o estudo da fragmentação para 
ambos os grupos de compostos, revelou que novos derivados podem ser previstos, tendo em conta, os princí-
pios estabelecidos. No que diz respeito à segunda parte, a aplicabilidade do método de screening foi avaliada 
tendo como base o HighResNPS. Durante este processo, foi explorada uma nova perspetiva, em como usar o 
HighResNPS sem necessidade de o importar. Assim, foi utilizada como uma base de dados espectral online, 
possibilitando o acesso imediato às informações mais recentes. De modo a testar o HighResNPS, 36 amostras 
confiscadas pelas autoridades Dinamarquesas durante o período de 2015 e 2019 foram analisadas utilizando 
UHPLC-QTOF-MS. Contudo, apenas 14 amostras de NSP desconhecidas foram selecionadas, uma vez que as 
restantes deram origem a resultados idênticos ou indicaram a presença de drogas tradicionais, tal como heroína 
e MDMA.  
No âmbito deste trabalho, a ionização por electrospray, no modo positivo, foi utilizada como fonte de iões. 
A deteção foi realizada com base numa aquisição de alta resolução de massa exata, através de um espectróme-
tro de massa de tempo-de-voo. Todos os dados foram processados com recurso ao UNIFI 1.9.2 e adquiridos 
por meio de um varrimento completo, com base numa aquisição independente de dados (AID) (data indepen-
dent acquisition, DIA). O processo de fragmentação foi induzido por uma rampa de energia de 10 a 40 eV. 
Para todas as 14 amostras, o ião precursor foi investigado no HighResNPS, utilizando pelo menos uma décima, 
de modo a reduzir, assim o número de potenciais candidatos, tendo como base a massa exata do composto. De 
seguida, o perfil de fragmentação foi examinado, correlacionando os dados obtidos com a informação dispo-
nível na biblioteca. Em suma, esta abordagem permite obter uma informação preliminar, podendo conduzir-
nos frequentemente à NSP certa. Contudo, em alguns casos nem sempre é possível definir uma estrutura quí-
mica rigorosa do composto, especialmente quando estamos perante isómeros posicionais. No entanto, podemos 
ter uma noção clara da classe de drogas a que este deve pertencer. Sendo, assim necessário nestas situações 
recorrer a outras metodologias como por exemplo, espectroscopia de ressonância magnética nuclear (RMN) 
(nuclear magnetic ressonance, NMR) ou adquir os padrões de referência, de modo a conseguir um resultado o 
mais exato possível.  
 
Palavras-chave: NSP; HighResNPS; screening; AID.  
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ABSTRACT  
New Psychoactive Substances, commonly referred to as NPS, are continuously emerging on the recrea-
tional drug market under appealing trade names and packages, sparking especially the curiosity of the youngest 
generation. These compounds are designed to mimic the effects of traditional illicit drugs and characterised by 
slightly modifications in their chemical structures. In this way, NPS represent a global concern to the public 
health owing to their unpredictable pharmacological and toxicological effects, thus leading to severe intoxica-
tions that might culminate in deaths.  
The term “new” could mislead their real definition, since some of them have been manufactured more than 
40 years ago for distinct purposes and recently, they have been reintroduced on the drug scene thanks to their 
psychoactive properties. In addition, they hold a label “not for human consumption”, in order to divert the 
attention from their actual composition and therefore, avoiding national and international laws. The identifi-
cation of NPS poses a challenge for the analysts that are willing to give an effective answer to the cases at 
hand, this is mainly due to structure similarity and lack of reference standards. In this way, this thesis aimed 
at improving and testing a universal online library named HighResNPS for NPS, when reference standards are 
not readily available, using ultra-high-performance liquid chromatography quadrupole time-of-flight mass 
spectrometry (UHPLC-QTOF-MS). Hence, the presented work was composed by two main parts: the database 
and the screening method. It was essential to ensure that the information contained on the HighResNPS was 
correct, in terms of fragment ions, IUPAC names, drug classes, among other parameters; in addition, the steady 
emergence of two specific NPS drug classes forced us to create two additional sub-libraries containing 51 
fentanyl analogues and 215 synthetic cannabinoids that could provide an insight into their fragmentation pat-
terns, which were further compared with the data available on the database. In general, the fragmentation study 
for both groups revealed to be successful and therefore, novel derivatives can be predicted based on the estab-
lished principles.  
Regarding the second part, the applicability of a screening method for NPS in seizures was evaluated using 
HighResNPS as an online mass spectral database. This analysis was performed exclusively to 14 seizures that 
were confiscated by the Danish authorities between 2015 and 2019 containing unknown compounds. Further-
more, the mass spectral was acquired in positive mode and in data-independent acquisition (DIA), being the 
fragmentation process induced by a ramp of collision energy (CE) from 10 to 40 eV. For all the aforementioned 
samples, the precursor ion was searched on HighResNPS by selecting at least one decimal, in order to reduce 
the number of potential candidates based on the accurate mass and then, the fragmentation profile was exam-
ined, correlating the data obtained with the one available on the database. In conclusion, the approach provides 
a preliminary information and it might often lead us to the correct NPS. However, in some cases it is not always 
possible to define the exact structure of the compound, nevertheless we can have an idea concerning the drug 
class within it might be included, this is observed for positional isomers when it is required to resort to other 
methodologies such as, nuclear magnetic resonance (NMR) spectroscopy or purchase the reference standards 
to obtain an unambiguous result.  
 
 
Keywords: NPS; HighResNPS; screening; DIA. 
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1 INTRODUCTION 
In this chapter, a literature review is presented comprising the relevant topics regarding the conducted work. 
The control of NPS in Europe, their classification system, the use of a database (HighResNPS) and the analyt-
ical tools applied for the screening of these drugs in seized material are described.  
1.1 Into the world of NPS 
New Psychoactive Substances, the so-called NPS, are a worldwide phenomenon that poses a threat to the 
public health 1. In the end of 2017, more than 670 NPS were recorded by the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) 2.  
The NPS concept might mislead its real definition, i.e.  the term “new” could lead naturally to the conclu-
sion that these substances are novel, however some of them were synthesized more than 40 years ago by 
researchers (e.g. John W. Huffman) in an attempt to improve the medical properties of cannabis 3. More re-
cently, their recreational use came into play 4. The main purpose of these drugs is to mimic the effects generated 
by well-known substances (e.g. cocaine, ecstasy, amphetamines and fentanyls 5), which are under control, 
producing a stronger impact on their users 1. Hereupon, what define NPS? According to the United Nations 
Office on Drugs and Crime (UNODC), they are described as “substances of abuse, either in a pure form or a 
preparation, that are not controlled by the 1961 Single Convention on Narcotic Drugs or the 1971 Convention 
on Psychotropic Substances, but which may pose a public health threat” 6. In other words, NPS also referred 
to as designer drugs, are characterized by a modification in their chemical structure; sometimes a replacement 
of a hydrogen for a halogen is enough to contribute to a more powerful effect and consequently, to circumvent 
the legislation 7. These substances can be easily manufactured by people who have an expertise in chemistry 
and the clandestine laboratories where their synthesis takes place, are predominantly based in China and less 
frequent in India 1. Afterwards, the drugs are distributed through the borders, maritime, air and terrestrial 8; 
until reach their destination, which is mainly Europe or America 1. Thus, the proliferation of NPS is evident 
all over the Internet 9, the major marketplace, but not only; they can also be purchased on smartshops as “bath 
salts” and “research chemicals” or by “street dealers” who obtain them from online shopping and then sell 
them in clubs, at music festivals and schools 1. In this way, they could be described as “party pills” 10. In 
addition, the products on sale hold a label “not for human consumption” as a strategy, in order to avoid national 
and international laws 11. The effects associated to its intake, may be diverse and sometimes unpredictable, but 
might range between stimulant, hallucinogenic and analgesic side effects, just to name a few 12.   
The rising wave of “legal highs” 13 has sparked the curiosity among the youngest generation specially owing 
to their affordability and anonymity 1. Besides that, the trade names given, and the packages used to sell NPS 
can also be attractive factors that make people want to try them out 8. In general, males are the most common 
consumers of these substances 6,14. Recently, a study carried out in six European countries (Ireland, Germany, 
Hungary, the Netherlands, Poland and Portugal) reported that males between 18 and 24 years old are in fact, 
the typical NPS users and depending on their living place (big or small cities) as well as, education level, they 
can be categorized into three groups (marginalized, nightlife and online users) 6. Therefore, the population 
target includes not just students and clubbers, but also LGBT, psychonauts, homeless and prison communities 
15,16. 
The fast-pace at which NPS emerge on the drug markets, makes it challenging to control them. When a 
drug comes to the attention of the authorities and finally is added on the list of controlled substances, a new 
one appears with the aim to replace it 17. This situation is rising frustration for the policy makers who are 
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willing to find an effective approach to regulate NPS 18. So, why is this so complex? The problem is that these 
drugs are recent on the market and therefore, their characterization is still under investigation once there is 
scarce analytical information on NPS and lack of reference standards 8. In this way, how can we detect NPS 
in seized material? This thesis aims at building a universal NPS screening library that can be employed by all 
high resolution mass spectrometers (HR-MS) without the use of reference standards. 
 
1.2 The control of NPS in Europe 
The rapid growth of NPS on the European drug market forced the authorities to find a reasonable method 
to tackle this issue and consequently, to protect the health of EU citizens 19. Thus, the EMCDDA in collabora-
tion with the European Union Agency for law enforcement cooperation (Europol) implemented in 1997 the 
European Union Early Warning System termed EWS, which is responsible for monitoring and detecting these 
novel drugs. In addition, this advisory system comprises 30 national early warning systems (28 member states, 
Norway and Turkey) and law enforcement networks such as, the European Medicine Agency and the European 
Commission providing risk assessments on NPS and communicating the information collected to the member 
states, so they can define their own preventive actions 20.  
In Europe, the NPS legislation system consists of a three-step process: 1) early warning or information 
exchange, 2) risk assessment and 3) control measures. The EMCDDA oversees the first two stages, which 
includes the management of the EWS and the risk assessments, while the last action is ruled by the European 
Commission, the Council of the European Union and the European Parliament 21. This approach was strength-
ened in November 2017 with the purpose to improve the Union’s response to NPS 22. So, how does it work? 
Considering the analysis of seized material, if any compound is suspected to be a NPS, the national early 
warning system should announce immediately the EMCDDA and provide chemical and analytical information, 
besides that the circumstances of the event may also be investigated. In case the suspicion is right, a formal 
notification is issued by the respective country 23. This comprises the following relevant aspects: the name and 
identifiers of the substance, the properties (chemical and physical), as well as the analytical methodologies for 
its identification, the pharmacology and toxicology 24. At this point, the monitoring of the substance takes 
place. In this way, the member states are aware about the new drug and therefore, ready to act accordingly. 
For example, in forensic laboratories it might be essential to include the substance in their analytical screening, 
particularly when the recent information can be helpful in analysing data that might have been missed during 
previous studies owing to the lack of knowledge 20. The first stage is completed after the evaluation of the need 
of a formal risk assessment, which means that the information regarding the novel substance is investigated 
and it will be documented on the so-called Joint Report (initial report). In this way, the Council may decide 
whether to undertake a risk assessment of the substance or not 24. It is also during this process that the potential 
risks and implications of adding it on the controlled substances list are examined. Furthermore, this drug is 
further subjected to a comparison with the compounds under control as well as others containing similar fea-
tures. However, when the substance reveals therapeutic benefits or it is applied in industry for developing 
medical products there is no need to conduct a risk assessment 24. This step is complete after the formulation 
of a report by the Scientific Committee. It should encompass an analysis description and any opinions regard-
ing the compound, more specifically: chemical and physical characteristics of the NPS in consideration, as 
well as the mechanisms of action, which may also include the medical value; potential risks for health and 
society; information concerning any detection by the authorities and its manufacture; definition of control 
measures in the member states and the chemical precursors used for its fabrication 25. Lastly but not least, the 
introduction of control measures which is decided by the Council and represents the final step. At this level, 
the member states need to define the rules and criminal penalties, they have one year from the date of the 
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decision to act in accordance with their national law 24. In this way, what is the criteria to add a certain com-
pound under control? Firstly, it is important to make sure that its psychoactive properties are clear, as well as 
the probability of generating abuse or dependence, which may result in hallucinations or disturbances in be-
haviour or perception, and the impact on public health. Furthermore, its use in medical therapy should be also 
taken into account 26.  
 
1.3 NPS categories 
The UNODC classifies NPS into six main categories: synthetic cannabinoids, synthetic cathinones, ket-
amines, phenethylamines, piperazines and plant-based substances. Besides these classes, a seventh cate-
gory can be mentioned – the miscellaneous, which corresponds to substances that do not fall into any of the 
indicated groups, such as aminoindanes, phencyclidine-type substances, tryptamines and benzodiazepines 27. 
This classification system is based on the chemical structure which characterizes the different compounds and 
allows the development of analytical methods for a proper identification 28. A general description for each 
category is presented below. 
1.3.1 Synthetic cannabinoids 
According to the EMCDDA, synthetic cannabinoids are widely controlled in Europe 29. This class of com-
pounds also referred to as SCs 30, emerged in the early 1960s with the purpose of boosting the anti-inflamma-
tory and analgesic properties of delta-9-tetrahydrocannabinol (THC)a 31,32, which is the main psychoactive 
component in the plant Cannabis sativa, also known as marijuana 33. Along the years, cannabis has been doc-
umented thanks to its medical benefits (e.g. 500 years ago the extracts of marijuana were applied to alleviate 
cramps and to treat malaria in ancient China) 30. However, more recently its recreational use has restrained the 
initial purpose 33.  Thus, it is considered a narcotic drug and is forbidden by the United Nations Single Con-
vention on Narcotic Drugs mainly due to its uncertain pharmacological effects and psychoactive properties 30. 
SCs bind to cannabinoid receptors of the organism, cannabinoid receptor type 1 (CB1) and cannabinoid 
receptor type 2 (CB2) generating effects, which are like the ones occurring in THC e.g. relaxation, disinhibi-
tion, euphoria and distorted perception 34. These receptors can be found in different parts of the body, CB1 is 
mostly present in the central nervous system whereas CB2 is predominantly located in the cells of the immune 
system 35. Although SCs and THC stimulate the same receptors, it is reported that the consume of SCs leads 
to a great number of hospital entrances as well as, a higher level of toxicity 31. This can be explained in terms 
of affinity 32, i.e. the measure of how strongly a drug molecule binds to a receptor 36. In light of above, the 
cannabinoid receptors have a higher affinity for SCs, which are recognized as full agonists 32, this means that 
SCs bind to receptors producing a full response 36, while THC is a partial agonist 32, in other words it acts as 
an agonist however, the effect generated is not as great 36, thus being less potent 37.  
It is worth noting that SCs are synthesised in laboratories (as powders) and not coming from Cannabis, 
which is sometimes misunderstood 37. Instead, most of these compounds are chemically fabricated in China 
and shipped to Europe, where their aspect is modified with the use of herb mixtures and solvents e.g. acetone 
or methanol, in order to disguise their real composition and therefore, make people think that the product is 
provided by natural sources 32. As a result, the consumers should suspect of the content, since unknown chem-
ical compounds can be added and in different compositions, which may lead to unpredictable effects 37.   
                                                     
a Controlled under the Schedules of the Convention on Psychotropic Substances of 1971 80 
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In the 2000s, new variations of SCs started to arise on Internet drug markets. Most of these novel com-
pounds are commercialized under the brand names such as “Spice”, “K2” or “Kronic”, depending on the part 
of the globe where they are sold. The first designation is more common in Europe; the second in the USA and 
the last one in Australia and New Zealand 32. They are usually on sale as legal highs and with a label describing 
that they are not for human consumption; additionally, no information regarding the health risks is mentioned 
32. However, the drug users’ who are mainly young people 38, report their preference for SCs specially because 
they can obtain these substances easily on Internet websites and smartshops on the condition of anonymity at 
a low price and they are a legal alternative to marijuana; besides that, the lack of reference standards make 
difficult their detection during a drug testing which is therefore limited to THC 32. Concerning the way of 
administration, they can be rolled in a paper cigarette, inhaled through an electronic cigarette or taken as an 
herbal infusion 32. It is important to highlight that the consume of SCs is strongly associated with acute intox-
ications and sometimes overdose deaths may take place 39. However, other side effects may occur but not as 
severe as aforementioned such as, tachycardia, chest pain, lethargy, nausea, hallucinations, amnesia, paranoia, 
panic attacks, shaking and renal damage 32,34.  
In 2010, an array of SCs started to be international banned 32. Nevertheless, the efforts were not enough to 
control the rapid emergence of these compounds, since every year a diversity of structures is launched on 
Internet drug markets 32. In this way, it is challenging to regulate this type of substances 32. The drugs available 
on online shopping and smartshops are homologues of SCs, which were first manufactured in the 1960s by 
researchers from different institutions or companies and to distinguish them, they have associated a code name 
derived from their initials 32.  “HU” series comes from the Hebrew University in Jerusalem, “CP” corresponds 
to Charles Pfizer & Company, “JWH” belongs to John W. Huffman and “AM” to Alexandros Makriyannis 
just to name a few 40. In Figure 1.1, some examples of the structures are given: HU-210 (a), CP 47497-C8 (b), 
JWH-018b (c) and AM-2201b (d), respectively 30.     
 
Figure 1.1 | Examples of the main SCs series. 
More recently, the EMCDDA stablished a method for naming compounds containing a long chemical name 
that can also be applied to emerging novel substances on the black market 40. In order to simplify, the code 
names are based on the International Union of Pure and Applied Chemistry (IUPAC) name of SCs and are 
given accordingly to the initials representing the structures present in the compound 40. For example, APICA 
                                                     
b Controlled under the Schedules of the Convention on Psychotropic Substances of 1971 80 
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illustrated in Figure 1.2, has the following systematic name N-(1-adamantyl)-1-pentyl-1H-indole-3-carbox-
amide which confirms the criteria i.e. A stands for adamantyl, P denotes pentyl, I designates indole and CA 
represents carboxamide. Furthermore, SCs can be characterized by four units: core, tail, linker and linked 
group 40. 
 
Figure 1.2 | APICA. 
The Advisory Council on the Misuse of Drugs (ACMD) reported that SCs can be classified into the main 
sub-groups: naphthoylindoles, naphthylmethylindoles, naphthoylpyrroles, phenylacetylindoles, cyclohex-
ylphenols and classical cannabinoids (Figure 1.3) 30,41-43. These categories have been in use until recently, 
however the rapid growth of SCs contributed to an outdated classification system. Since then, a number of 
chemical modifications have been stated, for example: the indole ring, which is common to JWH compounds 
was replaced by an indazole ring; furthermore, the carboxamide group and adamantane or quinoline ring make 
now part of their structure 44.  
 
Figure 1.3 | Examples of compounds belonging to the main SCs sub-groups: (a) naphthoylindoles, (b) naphthylmethylin-
doles, (c) naphthoylpyrroles, (d) phenylacetylindoles, (e) cyclohexylphenols and (f) classical cannabinoids.  
1.3.2 Synthetic cathinones 
Synthetic cathinones are recognized as the second predominant group of NPS monitored in Europe right 
after SCs 45. This class of drugs consists of chemical analogues of natural cathinone (Figure 1.4a), which is a 
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psychostimulant alkaloid present in the leaves of a plant named Catha edulis also known as khat, mainly found 
in northeast Africa and Arabia Peninsula 46. In addition, natural cathinone produces amphetamine-like effects; 
the relationship between this substance and amphetamine is illustrated in Figure 1.4.  
 
Figure 1.4 | (a) Natural cathinone and (b) amphetamine. 
Thanks to their ability to generate stimulant effects on the central nervous system (CNS), cathinones were 
originally applied for medical purposes, especially to treat patients with Parkinsonism 47. However, in the past 
few years their recreational use became relevant with the first appearance of two compounds, methcathinone 
(CAT) (Figure 1.5a) and mephedrone (4-MMC) (Figure 1.5b) 48. Nevertheless, the psychoactive properties 
of these derivatives were soon identified and consequently, their consume was forbidden 47. In this way, mod-
ifications in the structure of these drugs took place and hence, novel analogues started to emerge 49.  
 
 
Figure 1.5 | (a) Methcathinone and (b) mephedrone. 
In light of above, synthetic cathinones exert their action on CNS by inhibiting monoamine transporters such 
as, dopamine transporter (DAT), noradrenaline transporter (NAT) and serotonin transporter (SERT) 47,50. The 
affinity to these transporters might be different from derivative to derivative due primarily to variations in its 
chemical structure. Besides that, it should also be taken into account that the age, health condition, use of 
medication, intake of other substances of abuse and alcohol could influence the length of its action 47.  
These novel drugs commonly referred to as “bath salts” are sold under attractive brand names: “White 
Lightning”, “Bloom”, “Vanilla Sky”, among others 51. They can be found in the form of a powder, brown or 
white crystal-like, inside a plastic package holding a label “not for human consumption”, although “jewellery 
cleaner” and “phone screen cleaner” are also typical designations 51,52. In addition, it is important to reinforce 
that these packages might contain not only one compound, but instead a mixture of substances - caffeine and 
other illegal drugs - can be identified 53.  
It is worth noting that these drugs are intended for users that seek for legal substitutes of illicit psychostim-
ulants such as, cocaine, methamphetamine and MDMA (“ecstasy”) 54. Concerning the way of administration, 
they can be orally, intravenously and intranasal administered 13. Consequently, serious side effects to the hu-
man health can arise no matter the exposure degree: panic, hallucinations, paranoia, aggression and violence 
(i.e. suicide and homicide might be committed), chest pain, nausea, tachycardia and therefore, could culminate 
into death due mainly to liver and kidney failure 54,55. The latter reactions could last approximately 3 to 4 hours 
56. Over the course of the years, several fatalities have been linked to the consumption of these drugs, especially 
mephedrone, methylone and pentylone 2.    
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These legal highs came originally from natural cathinone and are considered chemical analogues of 
methcathinone 57. Based on their generic chemical structure (Figure 1.6), synthetic cathinones are character-
ized by a carbonyl group attached at the beta position on the amino alkyl chain, thus they are usually described 
as “bk-amphetamines” 58. 
A diversity of novel chemical entities can be easily generated by including new functional groups to the 
core skeleton, replacing one or more substituents on the phenyl ring (R1 and R2), at the alpha-carbon position 
(R3) and at the N-alkyl chain (R4 and R5) 59.  
 
Figure 1.6 | General structure of synthetic cathinones. 
Currently, the cathinone derivatives can be divided into the four groups as depicted in Figure 1.7 47,49:  
1. Consists of N-alkyl compounds or alkyl and halogen substituents in any position of the aromatic ring 
(e.g. flephedrone and 4-chloroethcathinone);  
2. Considers compounds with methylenedioxy groups in any position of the phenyl ring (e.g. methylonec 
and pentylone);  
3. Includes analogues of natural cathinone with a pyrrolidinyl substitution at the nitrogen atom (e.g. 
MPHP and 4-fluoro-PV9); 
4. Contains the methylenedioxy and N-pyrrolidinyl substituents (e.g. MDPPP and 3,4-MDPVc). 
 
 
Figure 1.7 | Examples of cathinone derivatives for each group. 
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1.3.3 Ketamines 
The scientist responsible for the first appearance of ketamine (Figure 1.8a) was Calvin Stevens from the 
Parke-Davis Pharmaceutical Company (Michigan, USA), which synthesized this compound in 1962 with the 
aim to discover an alternative to the hallucinogenic agent phencyclidine (PCP) (Figure 1.8b) 60. Thanks to its 
anaesthetic properties and rapid onset action, ketamine was primarily applied in the clinical field e.g. to treat 
problems with alcohol, heroin addiction, anorexia and depression 60,61. However, it was later found that this 
substance would be linked to psychedelic episodes, affecting the perception and mental state of patients 61. In 
this way, its use has been restrained 62.  
 
Figure 1.8 | (a) Ketamine and (b) phencyclidine (PCP). 
In the 1970s, this group of compounds emerged on the illegal drug market 62. At first, the users were 
healthcare professionals who could easily have contact with the drugs, but this scenario has changed a few 
years later and ketamines started to be a trend among club goers; in other words, they were commonly seen on 
the “rave scene” as an adulterant to ecstasy pills 62,63. The effects induced by its intake rely on the dose 61:  
▪ speech disorder, disorientation, anxiety and irrational behaviour (low doses);  
▪ respiratory disturbances, complications in moving, seizures and nausea (high doses);  
Lastly, loss of consciousness and paranormal experiences may occur at excessive dosage that may not ex-
ceed 2 mg/kg 61. Thus, ketamine is sometimes referred to as “dissociative drug” 64 due to the sense of discon-
nection of the mind from the body experienced by its users 65. However, overdose deaths are unlikely to take 
place owing to its broad therapeutic window 65 .  
These drugs of misuse are available on the black market as white powders and tablets 61 and are commer-
cialized under appealing street names such as, “Special K”, “Vitamin K”, and “Kit Kat” 66. Likewise in other 
NPS, ketamines are usually adulterated or combined with other components e.g. PCP, MDMA, cocaine, diaz-
epam and paracetamol 61. Concerning the administration routes, they can be intravenously, orally and intranasal 
administered 65.  
Ketamine belongs to the arylcyclohexylamines group 67. This class of compounds consists of a cyclohex-
ylamine unit with an aryl moiety (e.g. phenyl ring) attached to the atom to which the amine group is also linked 
67.  
The urge to manufacture novel analogues became relevant when ketamine started to be controlled in dif-
ferent countries 64,68. In this way, methoxetamine (MXE) (Figure 1.9) was one of the outstanding substances 
produced. This compound differs from ketamine in the following aspects 63:  
▪ the inclusion of the N-ethyl group that could boost the potency as well as its duration of action; 
▪ the replacement of the 2-chloro with the 3-methoxy group which could suggest the mitigation of its 
anaesthetic and analgesic features; 
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Figure 1.9 | Methoxetamine. 
However, MXE was later banned from the drug market 62. Hence, new analogues were fabricated (Figure 
1.10) 62.  
 
Figure 1.10 | Examples of new ketamine analogues: (a) 2-methoxyketamine and (b) N-ethylnorketamine (N-EK). 
 
1.3.4 Phenethylamines 
Phenethylamines (PEA) 69 are famous for their hallucinogenic properties 70. Mescalined (Figure 1.11) is 
the first alkaloid reporting these effects, which are produced by the peyote cactus (Lophophora williamsii) 71. 
In order to achieve a full reaction, it is recommended a high dose between 250-500 mg, which means that its 
effectiveness is poor. Nevertheless, this substance is believed to be the foundation to which new molecules are 
designed 71.   
 
It is worth noting that this class of compounds comprises amphetamine (see Figure 1.4b), methamphetamine 
(Figure 1.12a) and MDMA (Figure 1.12b), which are controlled under the 1971 Convention on Psychotropic 
Substances 72, therefore not considered NPS. They are usually found in the form of powders and tablets, being 
generally ingested 27. In addition, they are defined by different street names such as, “RDJ” and “Europa” 27.  
 
Figure 1.12 | (a) Methamphetamine and (b) MDMA. 
In terms of side effects, PEA are responsible for hallucinogenic and stimulant responses in the CNS, which 
can lead to disorientation, vertigo, nausea, headaches, among other symptoms 73. Concerning the fatalities 
record, the cases of heart attack stated are not many 74.  
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PEA are part of a major family of NPS named arylalkylamines 75 that encompass some of the following 
sub-groups: “2C series”, “D series”, NBOMe and benzodifurans 72. A brief description for each one is pre-
sented below.  
“2C series” (Figure 1.13) demonstrate a certain resemblance to the chemical structure of MDMA and it is 
suggested that they correspond to analogues of mescaline 72. Alexander Shulgin was the organic chemist re-
sponsible to give this designation to these substances, in order to represent the two carbons between the ben-
zene ring and amino group (see Figure 1.11) 70. Apart from that, he was the author of a book entitled “PIHKAL: 
A Chemical Love Story”, which comprises the information concerning the effects and dosages along with 
guidelines for the synthesis of more than 200 hallucinogenic compounds  72.  
 
Figure 1.13 | General structure of 2C series. R1 represents the possible substituents 72. 
In 1991, its publication led to a rise in popularity of the substances documented (e.g. 2C-B, 2C-T-7, 2C-E, 
2C-D, 2C-C, 2C-I, 2C-T-2, 2C-T-4, 2C-H, 2C-N and 2C-P) and consecutively to their restriction 72. This sub-
group can be characterized by a methoxy group at the positions 2 and 5 on the aromatic ring and a substituent 
(e.g. a halogen, alkyl and alkylthio moiety) at the para-position, which might produce an unlimited number of 
derivatives (Figure 1.14) 70. The potency of each substance may vary according to the substitution at the po-
sition 4 on the aromatic ring 72. It is reported that derivatives containing halogen substitutes are more powerful 
(i.e. the hallucinogenic effects are stronger) than the ones without these electronegative elements 72.  
 
Figure 1.14 | Examples of 2C series compounds from the book “PIHKAL: A Chemical Love Story” 72. 
From the chemical point of view, “D series” (Figure 1.15) involve the inclusion of a methyl group on the 
alpha carbon of the side chain, which differs slightly from the “2C series” 27.  
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Figure 1.15 | General structure of D series. R1 represents the possible substituents. 
DOBe, DOC and DOI are some examples that make part of this sub-group (Figure 1.16) 27.  
 
 
Figure 1.16 | Examples of D series. 
Afterwards, some adjustments were made on the “2C series”, therefore resulting in novel analogues 72. 
These new compounds correspond to the 2C-X-fly series, to which X refers to any substitute at the position 8 
and fly is attributed to two dihydrofuran rings attached to both opposite sides of the benzene ring (Figure 
1.17a) 72. Further, the aromatization of these heterocyclic compounds produced a different series named “drag-
onfly”; this term suggests that the chemical structures can be compared to an insect (Figure 1.17b) 72. Besides 
that, this group of drugs are reported to be extremely potent 72. 
 
 
Figure 1.17 | The benzodifurans sub-group – an example for each series: (a) 2C-X-fly and (b) “Dragonfly” 76. 
In 2011, the 25-X-NBOMe derivatives of the “2C series” emerged on the recreational market 12. These 
series are of major concern 70, since their intake can result in hallucination and delirium, which can be felt in 
a greater degree than in other 2C compounds 77. In addition, they are associated to repeated serious intoxica-
tions and deaths may occur 77. The NBOMe series consists of methoxy groups at the positions 2 and 5 on the 
benzene ring and replacement of one hydrogen (R3) from the amino group by an N-2-methoxybenzyl moiety 
(Figure 1.18a) 77. However, further structural modifications were performed 77. For example, 2,3-methylene-
dioxy or hydroxy groups were used in placed of the methoxy group from the N-2-methoxybenzyl moiety 77. 
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Moreover, 2,5-dimethoxybenzene is replaced by benzofurane (5-APB-NBOMe) (Figure 1.18b) or 3,4,5-tri-
methoxybenzene (mescaline-NBOMe) (Figure 1.18c) giving rise to novel representatives 77. 
 
Figure 1.18 | (a) General structure of NBOMe series where R1, R2 and R3 are the substituents, (b) and (c) that correspond 
to novel representatives 77. 
 
1.3.5 Piperazines 
At first, these compounds were developed for therapeutic purposes but rapidly their psychoactive properties 
came into play 27. In the late 1990s, this class of substances appeared on the drug market 78 with the aim to 
mimic the stimulant effects of MDMA; however, its potency is inferior 12. In this way, piperazines derivatives 
can be generally found in ecstasy tablets 79. Currently, these drugs are not included in any of the United Nations 
Conventions (1961 and 1971) 5,80, except 1-benzylpiperazine (BZP) (Figure 1.19a) which is already under 
international control 80.  
 
 
Figure 1.19 | (a) BZP and (b) TFMPP 80,82. 
These drugs are available in tablets or powders 81 and they can be consumed alone or as a blend 74 (i.e. a 
combination with other substances, such as a second piperazine, caffeine, cocaine and MDMA) 82, which may 
be taken orally or by snorting 81. In addition, they are usually found under some of the following trade names: 
“Bliss”, “Rapture”, “Legal X” 83. In case of BZP, this chemical is commonly mixed with 3-trifluoro-
methylphenylpiperazine (TFMPP) (Figure 1.19b), another piperazine derivative, to promote a long-term re-
action, usually up to 8 hours 82. Concerning the side effects, they may depend on the dosage; high portions 
could lead to hallucinations, disorientation, headaches and difficulties in breathing. In addition, seizures, kid-
ney failure and fatal intoxications are also reported 84.  
Piperazines (Figure 1.20a) consist of a six-membered ring containing two nitrogen atoms in opposite po-
sitions 85. From this structure, novel derivatives might be produced by introducing different functional groups 
at R1 and R2. In this way, two sub-groups can be generated: benzylpiperazines (Figure 1.20b) and phenylpi-
perazines (Figure 1.20c) that are mainly characterized by an aromatic ring attached to the piperazine moiety 
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to which BZP and TFMPP are included, respectively 85. Some other substances belonging to the sub-groups 
are presented in Figure 1.21 where R1= -H, -CH3 and R3= -CH3, -Cl, -F, -OCH3, -Br 82.  
 
Figure 1.20 | General structures of (a) piperazines, (b) benzylpiperazines and (c) phenylpiperazines, where R1, R2 and R3 
are the substituents 85. 
 
Figure 1.21 | Examples of piperazine derivatives for each sub-group: benzylpiperazines (a and b) 
 and phenylpiperazines (c, d, e and f) 82. 
 
1.3.6 Plant-based substances 
This class of compounds comprehends three different plants: khat, kratom and salvia divinorum. It is im-
portant to mention that any of them are listed in the United Nations Conventions (1961 and 1971). However, 
some countries have adopted some control measures to restrict their use among their population. For khat, 
cathinone and cathine, which make part of its chemical composition are already under international control 80.  
Khat named Catha edulis is a plant commonly found in the Horn of Africa and the Arabian Peninsula 86, 
which has an impact on the social and cultural life of the communities 87. In other words, chewing its leaves 
seem to be a regular practice among the indigenous people, as it induces pleasure and stimulant effects as well 
as contributes to enhance social interaction 88. This plant has been used as a drug of abuse and is available 
under the following street names: “Kat”, “Qat”, “Chat”, among others 89.  
Concerning its composition, the shrub contains essentially an array of alkaloids, flavonoids and glycosides 
86. Of these chemical components, cathinonef (see Figure 1.4a) and cathinef (Figure 1.22) are the most im-
portant and they are responsible for the amphetamine-like effects 87. Cathinone, the largest active constituent, 
releases catecholamines immediately after the leaves are chewed; this event can explain the stimulant actions, 
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which are known to be affected by the freshness of the leaves 90. On the other hand, cathine bears the respon-
sibility for the undesirable effects that might occur 91. In this way, fresh leaves are preferred owing to their 
higher content of cathinone to cathine, hence leading to minor side effects 91.  
In terms of adverse effects, it is worth noting that khat promotes an increase in blood pressure and heart 
rate. In case of long-term use, the manifestations might be more severe, such as neurological disorders, psy-
chosis, violence, organ damage, among others 4. In addition, the effects can remain up to 3 hours 89. 
 
Figure 1.22 | Cathine 87. 
 
Kratom also known as Mitragyna speciosa is a tropical tree indigenous to Southeast Asia (i.e. from Thai-
land, Malaysia, Myanmar, The Philippines and New Guinea), which has been disseminated globally through 
the Internet drug websites 92. Traditionally, the natives used to chew the leaves of kratom to make them boost 
their energy, besides that it was consumed as a replacement of opium and to control opioid withdrawal symp-
toms by chronic users 93,94.    
The main active components found in kratom are mitragynine (Figure 1.23a) and 7-hydroxymitragynine 
(Figure 1.23b) 95. These alkaloids compounds by binding the opioid μ-receptor can cause stimulation and 
sedation effects 95, which may differ in the dosage 96. Thus, small portions are associated with stimulant results, 
whereas large quantities (10-25 g of dried leaves) 97 lead to soothing reactions, which can be similar to that of 
morphine 98. The users might experience the following effects 93:  
▪ increased physical energy, alertness and sociable behaviour (low doses); 
▪ nausea, dizziness, sweating, euphoria, increased urination and loss of appetite (high doses) – these 
symptoms emerge within 5 to 10 minutes after ingestion and may remain up to 5 hours. It is worth 
noting that the consumption of kratom can lead to addiction. In addition, it is reported several cases of 
psychosis and some fatalities due to overdose.  
On the illegal drug market, kratom is regularly termed “Krypton”, which involves a combination of caffeine 
and O-desmethyltramadol 4,86. However, other street names can also be identified, such as “Thang”, “Thom” 
and “Ketum” 4. In terms of administration, ingestion seems to be the major mode of intake 4.   
 
 
Figure 1.23 | (a) Mitragynine and (b) 7-hydroxymitragynine 95. 
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Salvia divinorum or salvia is a plant native to the state of Oaxaca (Mexico) 99, which is known to contain 
hallucinogenic properties 100. Originally, it was described for medical, spiritual and religious purposes 101. The 
main active component found in this plant is termed salvinorin A (a non-alkaloid agent) (Figure 1.24) 86 that 
might contribute to its psychedelic effects, such as dizziness, distortions of objects, hallucinations, decreased 
ability to interact with the surroundings and overlapping realities 102. These effects occur within 5 to 10 minutes 
after ingestion 102 (i.e. by chewing, swallowing or smoking) 103. In other words, the leaves can be chewed, 
taken as an infusion or smoked 103. Depending on the mode of use, the reactions might have a short or long-
term action (i.e. from a few minutes to 2 hours) 101. On the recreational market, salvia is available under the 
following street names: “Diviner’s Sage”, “Sally-D”, “Magic Mint”, among others 4.   
 
Figure 1.24 | Salvinorin A 86. 
 
1.3.7 Miscellaneous group 
This group comprises substances that do not fit into the aforementioned categories. In this sense, they can 
be divided according to their psychoactive effects: stimulants (e.g. aminoindanes), dissociatives (e.g. phen-
cyclidine-type substances), hallucinogens (e.g. tryptamines), opioids (e.g. fentanyls) and sedatives/hypnot-
ics (e.g. benzodiazepines).  
Aminoindanes (AIs) possess analgesic and bronchodilating features 4. The derivatives emerged on the drug 
market are fabricated based on the structure of 2-AI (Figure 1.25a) 104, which is an analogue of amphetamine  
(see Figure 1.4b) 105. In this way, the inclusion of functional groups 106 to the 2-AI backbone structure may 
produce a diversity of chemical structures, such as 105: 
▪ 5-IAI (Figure 1.25b) with the addition of an iodine atom at the position 5 on the aromatic ring;  
▪ MMAI (Figure 1.25c) and MEAI (Figure 1.25d) characterized by methoxy and/or methyl groups; 
▪ MDAI (Figure 1.25e) and MDMAI (Figure 1.25f) includes a methylenedioxy bridge and/or N-alkyl-
ation. 
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Figure 1.25 | (a) The 2-AI backbone structure, (b), (c), (d) and (f) represent some examples of AIs 104,105.  
Phencyclidine-type substances exhibit a comparable structure to ketamines (see section 1.3.3); therefore 
making also part of the arylcyclohexylamines group 27. PCPg (see Figure 1.8b) contains potent analgesic and 
dissociative properties 107. At the beginning, this drug was developed as an intravenous anaesthetic; however, 
their users experienced adverse effects (e.g. agitation, psychosis and delirium), which lead to the withdrawal 
from clinical use 62. Later, PCP emerged on the recreational market as a white powder, tablet or liquid forms 
under the street names: “Angel Dust”, “Ozone”, “Rocket Fuel”, among others 108. Some PCP analogues are 
illustrated in Figure 1.26 62 . The effects produced may range between stimulant and depressant depending on 
the administration route, as well as dosage 109. According to the way of administration, it can be snorting, 
swallowing and smoking, being the latter one the most frequent method of use 108. In terms of dosage, low 
portions (i.e. 1 to 5 mg) cause apathy, blank stare, detachment feelings, and loss of coordination 108. On the 
other hand, high quantities may result in hallucinations, increased blood pressure and heart rate 108.  
 
Figure 1.26 | Examples of PCP analogues: (a) 3-MeO-PCP and (b) 3-HO-PCP 62. 
 
Tryptamines (Figure 1.27a) 110 came from the decarboxylation of the amino acid tryptophan (Figure 
1.27b); both share an indole ring and aminoethyl group at position 3 74,111. Chemical modifications in the 
skeleton structure of tryptamine may contribute to novel derivatives, which might affect the physical and men-
tal health of their users 112. Tryptamines became famous thanks to the publication of the book “TIHKAL: The 
continuation”, who the author is Alexander Shulgin 111. These compounds are sold in the form of powders or 
tablets, which can be consumed by ingestion, snorting, inhalation and smoking 74. 
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Figure 1.27 | Structures of (a) tryptamine and (b) amino acid tryptophan.   
In terms of classification, they can be split into three different groups, which are illustrated in Figure 1.28 
112: 
▪ tryptamines without any modifications on the indole ring (e.g. DETg and DMTg); 
▪ tryptamines with an alteration at the position 4 on the indole ring (e.g. 4-OH-DiPT and 4-MeOH-
MiPT);     
▪ tryptamines comprising a substituent at the position 5 on the indole ring (e.g. 5-MeO-DET and 5-
MeO-DMT). 
The recreational use of these substances is associated with psychotropic events and a high exposure to 
overdose 112.  
 
Figure 1.28 | Tryptamines classification: unsubstituted indole ring (a and b), 4-substituted (c and d) and 
 5-substituted (e and f) 112. 
 
In 1960s, fentanyls (Figure 1.29a) 113 were manufactured with the purpose to alleviate acute and chronic 
pain, which was possible due to their ability to bind μ-opioid receptors producing anaesthetic effects 114. It is 
worth noting that fentanyls are more powerful (i.e. 100 times)  in comparison with morphine 114, thus they 
became a valuable analgesic substitute in clinical use 114, thanks to their rapid onset and short duration of action 
115. In this way, the outset of their recreational abuse might be connected with the easy access to these sub-
stances by health professionals 114. Thereafter, fentanyls have increased in popularity and consequently, ex-
panded to the general public 114. The illicit use may lead to overdose deaths, as they possess a low lethal dose, 
which means that an intake of a few milligrams is fatal for their users 114 – respiratory arrest and pulmonary 
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edema might emerge 116. Despite the aforementioned consequences, other side effects not as severe may occur, 
such as sedation, dependence, breathing disturbances, nausea, dizziness, fatigue, among others 116. Concerning 
administration routes, they can be intravenously, intramuscularly or transdermal administered 117. Chemical 
modifications by introduction of functional groups on the piperidine and/or phenyl ring for example, might 
produce novel analogues (Figure 1.29) 113,117. Currently, the previous derivatives are under international con-
trol 80.  
 
Figure 1.29 | (a) General structure of fentanyls, where R1,R2,R3,R4, R5, R6, R7 and R8 represent the substituents, (b), (c), 
(d) and (e) are fentanyl analogues 113,117. 
 
Benzodiazepines are referred to as central nervous system (CNS) depressants, which replaced barbiturates 
frequently recommended to treat anxiety and sleep disorders, owing to their minor adverse effects and low risk 
of provoking an overdose 118. Nevertheless, this class of drugs exhibits a potential of misuse and dependence 
119. Their abuse comprises the combination with other controlled substances, such as opiates, methadone and 
cocaine 118. It is worth noting that opiates along with benzodiazepines could promote increased euphoric effects 
118. In addition, these drugs mixed with alcohol might lead to several cases of poisoning. In this way, fatal 
intoxications are more likely to occur when benzodiazepines are abused not as single substances 120. The emer-
gence of these substances as designer drugs started in 2011 with the appearance of pyrazolam (Figure 1.30) 
in forensic cases 119,121. Later on, novel derivatives came out on the drug market; they are mainly characterized 
by slightly modifications in their chemical structures 120.  
INTRODUCTION 
 
19 
 
 
Figure 1.30 | Pyrazolam 119. 
The backbone structure of benzodiazepines consists of a diazepine ring fused to a benzene ring 122. In gen-
eral, to this diazepine ring a phenyl ring is attached 122. Hence, based on tiny alterations, it is possible to dis-
tinguish them into several sub-classes (Figure 1.31). The manufactured analogues were founded on 1,4-ben-
zodiazepines 120. Therefore, the addition of a cyclic system (e.g. a triazole, imidazole and oxazole ring) to the 
previous chemical structure could give rise to triazolobenzodiazepines, imidazobenzodiazepines and oxazolo-
benzodiazepines, respectively 122. Furthermore, the replacement of the benzene ring with a thiophene ring (i.e. 
thienodiazepines) and lastly, the trienotriazolodiazepines that possess a thiophene and a triazole ring fused to 
the diazepine ring 122. These synthetic benzodiazepines are available in an array of dosage forms, such as 
powders, capsules and tablets 120. In terms of effects, they may range between anxiolytic, sedative and hypnotic 
side effects, which differ in the dose 119.   
 
Figure 1.31 | Some benzodiazepines sub-classes: (a) 1,4-benzodiazepines, (b) triazolobenzodiazepines, (c) 
imidazobenzodiazepines, (d) oxazolobenzodiazepines, (e) thienodiazepines and (f) trienotriazolodiazepines. R represents the 
substituents 122. 
 
1.4 Identification Methods of NPS 
In forensic laboratories, gas chromatography-mass spectrometry (GC-MS) has been referred to as a gold 
standard technique for the identification of traditional drugs 123. However, the appearance of NPS on the drug 
market revealed the method to be incomplete in pinpointing these compounds 123. In other words, the use of 
GC-MS databases is often restricted due to the lack of mass spectra concerning these novel substances 123. 
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Besides that, the structural similarity of these psychoactive compounds is not always evident, which might 
lead to unreliable interpretation when the analysis is only based on an electron impact-mass spectrometry (EI-
MS) spectrum 123. Moreover, the use of EI as an ionisation technique makes their determination challenging, 
especially when the produced ions correspond to low intensity fragments 123. Therefore, it is necessary to resort 
to more sophisticated techniques to address the previous issues. In this sense, high-resolution mass spectrom-
etry (HRMS) can be an alternative in the analysis of narcotics, since it provides an accurate mass of the ana-
lytes, allowing to elucidate their molecular formulae and as consequence, the list of possible candidates can be 
reduced to one or to a limited number of compounds, which can be further investigated in available databases 
124. In recent years, LC tandem MS or LC high-resolution (HR)-MS such as, the hybrid quadrupole time-of-
flight (QTOF), became commonly used for the identification, determination and quantification of NPS 125.  
After the sample preparation, the extract is separated in a liquid chromatogram. Of note, LC is characterised 
by its versatility owing to its ability to separate volatile and non-volatile compounds 126. Improvements on this 
technique led to columns containing particle sizes lower than 2 μm 125 and a higher temperature tolerance, 
which contributed to an enhanced separation of the substances and a shorter analysis time, these novel features 
gave rise to the ultra-high performance LC, the so-called UHPLC 127. Before the analytes enter on the mass 
analyser, they are ionised in the LC-MS interface (i.e. ion source), producing gas-phase ions. On the framework 
of this thesis, electrospray ionisation (ESI) was employed, since it is suitable for both small and large molecules 
within a broad polarity range 125. This ionisation technique is produced by applying a strong electric field under 
atmospheric pressure to the liquid, thus generating charged droplets. Depending on the ionisable sites, it is 
possible to observe substances carrying multiple charges, which is more likely to occur in proteins 123. On the 
other hand, some molecules do not comprise any ionisable sites, therefore the formation of adducts (e.g. so-
dium, potassium and ammonium) is prone to take place 123. It is important to notice that ESI is described as a 
soft ionisation method, in this way nearly no ion fragmentation is present during the ionisation process 125. 
Hence, it is expected to obtain protonated molecular ions (M+H)+, sodium and potassium adducts or deproto-
nated molecular ions (M-H)-, formate and acetate adducts, which rely on the operation mode positive and 
negative, respectively 125. It is worth noting that most of NPS are positive-ionised 123. In light of above, ESI 
may lead to insufficient information on fragmentation 123. To surpass this drawback, the fragmentation might 
be forced by a fragmentor voltage, causing the ions to collide with other molecular species (e.g. gas molecules), 
consequently the energy generated will promote the fragmentation to ensue 123. This technique is termed in-
source fragmentation, also known as in-source collision-induced dissociation (in-source CID) 123. Based on the 
fragmentor voltage, the degree of in-source fragmentation can be determined 123.  
In a QTOF, the quadrupole (i.e. a mass filter) is composed by four parallel rods where a voltage is applied 
producing an electric field that allows the selection of ions with a particular mass-to-charge ratio (m/z) and 
consequently, their routing to the detector 123. Before that, the ions undergo fragmentation that occurs in the 
collision cell by the contact with an inert gas (e.g. nitrogen, argon) 123. According to the collision energy (CE), 
the dissociation of the analyte may drive to different ion intensities which are hinge on the strength of each 
bond in a molecule 123. Therefore, the fragmentation may result in the source or in the collision cell 123. It is 
important to highlight that insights into fragmentation patterns of specific NPS drug classes are crucial for a 
proper structure elucidation of the compound at hand 123. As mentioned previously, the fragmented ions move 
along a flight tube with a reflectron that compensates the dispersion of kinetic energy of those ions with the 
same m/z, so that the ions can reach the detector at the same time, generating the mass spectrum 128. Of note, 
the smaller ions arrive at the detector earlier 128.  
In terms of data acquisition, HRMS can operate in data-independent acquisition (DIA) (Figure 1.32a) and 
data-dependent acquisition (DDA) (Figure 1.32b) modes 128,129. Thus, in DIA all ions recorded in the mass 
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analyser are further fragmented in the collision cell, whereas DDA mode works differently, which means that 
for this technique a specific precursor ion is selected instead 129. The former approach is more applicable to 
high-resolution instruments and provides with retrospective data interrogation allowing the analysts to reana-
lyse a sample without the need to reinject in the system 129. Besides that, it has the ability to acquire data by 
switching between low- and high-energy in the same run 129. DIA allows to obtain accurate mass of the pre-
cursor and product ions for structure characterisation. This acquisition mode is also referred to as all-in-one, 
the so-called MSE, where E stands for collision energy and is developed by Waters Corporation, Milford, 
Massachusetts, United States of America 128,129. The use of DIA might compromise the spectra interpretation, 
since it does not select a particular precursor ion, thus the association of the product ions with a correct pre-
cursor ion may be complex 129. However, this pitfall is improved when UHPLC is combined with QTOF con-
tributing to a better separation 128. In conclusion, HRMS contributes with putative structural elucidation that 
might be confirmed using nuclear magnetic resonance (NMR) spectroscopy, especially when positional iso-
mers are involved 129. In addition, LC-ESI-QTOFMS can be applied as an add-on method to GC-EI-MS, which 
is routinely operated in forensic laboratories 123. In this sense, the mechanisms of fragmentation under different 
ionisation techniques will promote different spectra, resulting in supplemental information on fragmentation, 
which is essential for the determination of NPS 123.  
 
 
Figure 1.32 | DIA and DDA acquisition modes. 
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1.5 HighResNPS database 
In 2016, an Internet mass spectral database for liquid chromatography-mass spectrometry (LC-MS) was 
created by a group of Danish researchers from the Department of Forensic Medicine of the University of 
Copenhagen and Aarhus University. The purpose of this database is trying to keep the libraries updated for 
screening of NPS, which is mostly challenging due to the continuous growth of these drugs into the black 
market and lack of reference standards. HighResNPS (Figure 1.33) is a crowd-sourced and free-of-charge 
database that has the contribution of a diversity of laboratories spread around the world, however is only de-
signed for a closed user group within the forensic field 130,131. The different contributors define their experi-
mental setup and location, so that new entries can be added 132. The records should contain the exact mass of 
protonated molecular ions with exact mass of up to three highest intensity fragment ions, retention time (Rt), 
International Chemical Identifier (InChI) key, systematic name (IUPAC) and respective drug class 132. In ad-
dition, the acquired mass spectra can also be included 132. Of note, the database can further be exported as an 
Excel spreadsheet, which makes it useful, distinguishable from other NPS libraries and compatible for HR-
MS screening platforms such as, Agilent QTOF MS, Bruker QTOF MS, Waters QTOF MS or Thermo Orbitrap 
MS 130. 
 
Currently, there are 19 countries (Australia, Belgium, Canada, Croatia, Denmark, Finland, Germany, 
Greece, Hong Kong, Italy, New Zealand, Norway, Portugal, Scotland, Spain, Switzerland, The Netherlands, 
The United Kingdom and The United States) involved in the database project. However, only a few of them 
are active users and have contributed with relevant data in the last months of 2018 and at beginning of 2019, 
especially Australia, Denmark, Finland, Norway and the United Kingdom.  
Regarding the classification drug system employed on the database, there are some slight variances in com-
parison with the UNODC categorization. The compounds can be grouped into the following categories: ami-
noindanes, arylalkylamines, arylcyclohexylamines, benzodiazepines, cannabinoids, cathinones, indolalkyla-
mines, opioids, phenethylamines, piperazine derivates, piperidines & pyrrolidines, plants & extracts and un-
known (Figure 1.34). The latter class corresponds to substances that do not fall into any of the previous groups.  
 
 
Figure 1.33 | HighResNPS overview: front-page. 
INTRODUCTION 
 
23 
 
 
Figure 1.34 | Drug classes on HighResNPS database with a characteristic compound: (a) aminoindanes, (b) 
arylalkylamines, (c) arylcyclohexylamines, (d) benzodiazepines, (e) cannabinoids, (f) cathinones, (g) indolalkylamines, (h) 
opioids, (i) phenethylamines, (j) piperazine derivates, (k) piperidines & pyrrolidines and (l) plants & extracts. 
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2 AIMS OF THE STUDY  
The main purpose of this thesis is to improve and test a universal online library (HighResNPS) for NPS 
when reference standards are not available using UHPLC-QTOF-MS (ultra-high-performance liquid chroma-
tography quadrupole time-of-flight mass spectrometry). In order to achieve this, the project was divided into 
two parts, which are briefly described below.   
   
Part I – HighResNPS 
▪ To monitor six drug websites: chem.eu, drugs-forum.com, erowid.org, EWS forum, forendex and 
NMS labs, so that novel compounds could be added on the database. The obtained data consists of 
non-experimental parameters (e.g. exact parent mass, molecular formula, InChIKey, IUPAC name 
and drug class); 
  
▪ To validate the database by including new features – this comprehends the correction of parent and 
fragment ion masses, as well as finding the missing fragment formulae and lastly, deleting all the 
double entries reported by RESPONSE and EMCCDDA libraries (i.e. the ones containing only parent 
masses); 
 
▪ To create two sub-libraries for synthetic cannabinoids and fentanyl analogues comprising information 
concerning the predicted fragment ions.  
   
Part II – Screening 
▪ To develop and evaluate the applicability of a targeted screening method for 14 NPS in seized material 
using UHPLC-QTOF-MS and HighResNPS as an online mass spectral database.  
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Chemicals and reagents  
All solvents were liquid chromatography-mass spectrometry (LC-MS) grade. Methanol, water, formic acid 
and acetonitrile were purchased from Fisher Scientific (Leicestershire, United Kingdom), whereas ammonium 
formate was supplied by Sigma-Aldrich (Steinheim, Germany). The TOF solution consisted of a water:meth-
anol:formic acid (74:25:1, v/v/v) mixture and an internal standard (carbamazepine at 1 mg/mL) prepared by 
the Section of Forensic Chemistry (Copenhagen, Denmark).  
 
3.1.2 Seized material  
36 seizures were confiscated by the Danish authorities during the years 2015 and 2019. The analysed ma-
terial consisted of powders, tablets and herbal matrices. 
  
3.2 Screening method  
3.2.1 Sample preparation 
50 mg of seized material was extracted in 5 mL methanol on a rotator PTR-35 vertical multi-function (Grant 
Instruments, Cambridge, United Kingdom) for 10 min followed by centrifugation on a ROTOFIX 32 A (Het-
tich,Tuttlingen, Germany) for 5 min at 3000 rpm. The prepared solution was further filtrated and diluted in 
two steps to a factor of 500 using the TOF solution.   
 
3.2.2 Ultra-performance liquid chromatography 
The chromatography was performed using a Waters ACQUITY UPLC system from Waters Corporation 
(Milford, Massachusetts, United States of America). The autosampler injected 3 μL of extract into an AC-
QUITY UPLC HSS C18 column (2.1 mm x 150 mm, 1.8 μm) maintained at 50 ⁰C in a column oven. 
LC separation of the samples was performed through a gradient profile of mobile phase A and B solutions, 
consisting of 5 mM aqueous ammonium formate buffer adjusted to pH 3 with formic acid and acetonitrile with 
0.1% formic acid (v/v), respectively. The gradient was 0 min to 0.5 min: 13% (B); from 0.5 min to 10 min: 
13% to 50% (B); from 10 min to 10.75 min: 50% to 95% (B); from 10.75 min to 12.25 min: 95% (B) and from 
12.25 min to 15 min: 95% to 13% (B). The flow rate was 0.4 mL/min and the total run time was 15 min. 
 
3.2.3 Mass spectrometry 
An orthogonal accelerator quadrupole time-of-flight mass spectrometer, Xevo G2-S QTOF (Waters MS 
Technologies, Manchester, United Kingdom) was used for screening of NPS in positive electrospray ionization 
(Z-spray) mode. The following settings were employed: nebulization gas 800 L/h, with a temperature of 400 
⁰C; cone gas flow 20 L/h; source temperature 150 ⁰C; capillary voltage 800 V; cone voltage 25 V and argon 
was used as collision gas. Data was recorded in DIA with elevated collision energy (MSE). The low collision 
energy (CE) was set at 4 eV and high CE ramped from 10 to 40 eV. The acquisition time was the entire run, 
with a scan time of 0.200 s. The mass range was from m/z 50 to m/z 950. For resolution measurement and 
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guarantee of reproducibility and accuracy, a LockSprayTM was applied. Lock mass was used with leucine 
enkephalin as a reference mass at m/z 556.2766.  
 
3.3 Software 
3.3.1 Data Analysis 
The data acquisition and data processing were performed with the UNIFI Scientific Information System 
(Waters) version 1.9.2 (Waters Corporation, Milford, Massachusetts, United States of America). The UNIFI 
software ensures that only relevant ions are selected and associated with a specific component. In addition, the 
elemental composition of the substance under investigation is automatically calculated and searched against 
internal libraries and databases using both precursor and fragment ion data (e.g. HighResNPS database). It also 
provides in-silico fragmentation information, assigning plausible or likely structures to the observed ions, 
which is helpful when standards are not available or difficult to purchase. To identify the substances the m/z 
tolerance for both precursor and fragment ions was 3 mDa.  
 
3.3.2 Chemical Drawing Software  
All chemical structure generation and fragmentation prediction were carried out by ChemBioDraw Ultra 
16.0 (PerkinElmer, Waltham, Massachusetts, United States of America). 
 
3.3.3 OPSIN 
This platform was used to generate the chemical name into a structure. It also comprised the InChIKey 
associated to that specific molecule, which allowed to make sure that the compound corresponded to the right 
chemical identifier or the other way around. This open source was useful during the first part of the thesis 133, 
134.  
3.4 Database 
3.4.1 mzCloudTM 
An Internet database of high-resolution tandem mass spectra containing a freely searchable collection of 
accurate mass spectra 135. This platform was used for assisting on the analytical identification and interpretation 
of the absent fragment ions, fragmentation prediction (part I: HighResNPS database) and in the last part of the 
thesis for spectra comparison (part II: screening method). 
  
3.5 Additional libraries 
3.5.1 TiHKAL 
An online library was used to search for the absent IUPAC names, InChIKey identifiers and possible syn-
onymous for a specific substance (HighResNPS database validation process) 136. 
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3.5.2 RESPONSE and EMCDDA 
RESPONSE 137 and EMCDDA libraries provided initially new entries to HighResNPS database. Both con-
tributed with chemical information such as, molecular formula of the substance of interest, InChIKey, IUPAC 
name and drug class.    
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4 RESULTS AND DISCUSSION 
In this section, the work conducted will be described in detail. In order to provide an overview of the results 
obtained, the study was divided into two main parts, the first one is related to optimizing the database and the 
second to testing it to screen for NPS.   
4.1 Part I – HighResNPS database 
The exponential growth of NPS on the illegal drug market forced the forensic laboratories to find a different 
approach to screen these designer drugs. NPS represent a challenge for analysts that are willing to give a 
reliable answer to the cases at hand; this is due to the limited information on the pharmacological and toxico-
logical effects. Besides that, the slight modifications in their chemical structures may compromise the analysis, 
in this way leading to a non-accurate interpretation owing to the structure similarity and the lack of reference 
standards, which are not always readily available. In order to try to tackle these issues, a group of Danish 
researchers had the idea of creating a database named HighResNPS.com. This database presents unique fea-
tures that may distinguish it from commercial databases. It comprehends new psychoactive substances as well 
as related compounds reported from an array of laboratories around the world. In this way, the same compound 
can have more than one entry, which contributes for self-validation, in other words it is possible to make sure 
that the data provided is correct. As mentioned previously, 19 countries are involved in the project: Australia, 
Belgium, Canada, Croatia, Denmark, Finland, Germany, Greece, Hong Kong, Italy, New Zealand, Norway, 
Portugal, Scotland, Spain, Switzerland, The Netherlands, The United Kingdom and The United States. How-
ever, only a few of them are in fact, active users. Since the last months (October, November and December) 
of 2018 to the beginning of 2019, merely Australia, Denmark, Finland, Norway and United Kingdom have 
been devoted to the database. Currently, HighResNPS comprises 4 analytical instruments: Agilent QTOF MS 
from Adelaide (AU), Oslo (NO) and Trondheim (NO); Bruker QTOF MS from Athens (GR), Helsinki (FI) 
and Aarhus (DK); Waters QTOF MS from Copenhagen (DK), IUPA, UJI (ES), Labor Krone (DE) and 
RCMP-NFLS (CA); Thermo Orbitrap MS from Copenhagen (DK), LGC (UK) and Mario Negri laboratory 
(IT). On the framework of this thesis, two additional sub-libraries: Fentanyl Analogues and Synthetic Can-
nabinoids Fragment Prediction from Copenhagen (DK) were included on the database. Both comprehend 
theoretical information on fragmentation, thus they do not contain any method associated. 
The first part of the thesis consisted of improving the database, so that it could be further downloaded and 
converted to a suspect library for Agilent QTOF MS, Bruker QTOF MS, Waters QTOF MS or Thermo Or-
bitrap MS. In order to achieve the aim, the former step involved the NPS classification of substances whose 
drug classes were absent. According to the UNODC categorization, it is possible to distinguish NPS into seven 
main classes: synthetic cannabinoids, synthetic cathinones, ketamines, phenethylamines, piperazines, plant-
based substances and miscellaneous (aminoindanes, phencyclidine-type substances, tryptamines and benzodi-
azepines) (see section 1.3). Nevertheless, HighResNPS does not follow the exact same criteria. The classifi-
cation drug system employed includes the following 13 categories: aminoindanes, arylalkylamines, arylcyclo-
hexylamines, benzodiazepines, cannabinoids, cathinones, indolalkylamines, opioids, phenethylamines, piper-
azines derivatives, piperidines & pyrrolidines, plants & extracts and unknown. Arylalkylamines are composed 
by phenylalkylamines (e.g. phenethylamines) and indolalkylamines (e.g. tryptamines); arylcyclohexylamines 
consist of ketamines and phencyclidine-type substances; opioids comprise compounds of natural, semisyn-
thetic, synthetic and endogenous origin that interact with opioid receptors, of which fentanyl analogues belong; 
piperidines & pyrrolidines are not considered in the UNODC NPS categories; unknown does not mean the 
compounds are unrecognized, instead they do not fall into any of the prior classes and the remaining groups 
do not suffer any modifications. Regarding arylalkylamines, this drug class comprehends a broad number of 
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compounds, especially phenethylamines and indolalkylamines that contain their own specific group on the 
database. In order to simplify, all substances that do not present an identical chemical structure to phenethyla-
mines and indolalkylamines are considered part of arylalkylamines (see section 1.5; figure 1.29b).  
At the beginning of this work, the database contained 1671 entries (Figure 4.1a) of which 706 were missing 
their NPS classification. Due to the number of multiple entries for the same substance, it is important to refer 
to these numbers in terms of compounds that were on the database at that time. After downloading the database 
into an Excel file, it was possible to conclude the presence of 1095 compounds: 7 aminoindanes, 25 arylalkyl-
amines, 19 arylcyclohexylamines, 37 benzodiazepines, 350 cannabinoids, 157 cathinones, 63 indolalkyla-
mines, 104 opioids, 163 phenethylamines, 29 piperazine derivatives, 27 piperidines & pyrrolidines, 19 plants 
& extracts and 95 unknown (Figure 4.1b).  
 
Figure 4.1 | HighResNPS database in October 2018: (a) number of entries and (b) number of compounds per drug class. 
A second step was monitoring drug websites, in order to add some emerging compounds or others of interest 
on the database. This process took place from end of October to middle of November 2018. During this period, 
58 novel substances were included on the database (see Appendix A) with their respective molecular formula, 
exact parent mass, drug class, IUPAC name and InChIKey (non-experimental data). Six drug websites were 
controlled: chem.eu, drugs-forum.com, erowid.org, EWS forum, forendex and NMS labs. Chem.eu 138 is an 
online market that sells research chemicals all over the world; drugs-forum.com is an informational website 
regarding drugs and their psychoactive effects 139; erowid.org is a forum where people describe their experi-
ences with psychoactive plants and chemicals, documenting how and why they are using a specific drug 140; 
EWS forum provides information concerning new drug trends among EU member states; forendex is an Amer-
ican website that lists the novel compounds on the drug market 141 and NMS labs offers a comprehensive test 
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portfolio for NPS to support medical examiners, law enforcement agencies, crime laboratories and healthcare 
providers 142.  
Afterwards, it was necessary to validate the database. The validation process is of paramount importance, 
since it is essential to ensure that the available data is accurate and there are not flaws that may weaken its 
potential. In this sense, we realised that mass errors associated with both parent and fragment ions were the 
most evident along the library, a simple mistake in entering one digit may ruin the entire information. Thus, it 
was incorporated an integrated calculator, so that the errors would come up automatically in red with the re-
spective difference, as illustrated in Figure 4.2. This tool allowed to find 290 entries comprising incorrect 
values for both parent and fragment ions, which were further revised.  
 
Figure 4.2 | Alpha-Methylfentanyl (opioid): first fragment mass with the right value highlighted in red (201.1512 Da).  
Besides that, fragment ion masses as well as their respective molecular formulae were in some cases not 
present or not matching accordingly. In this way, to find the molecular formulae of the missing fragments, the 
database was downloaded as an excel file and a pivot table was used. By combining the molecular formula, 
mass of each fragment and respective ID, it is possible to know how many fragments do not have associated a 
molecular formula. The following methodology was applied: 
▪ Filter: F1MF, F2MF or F3MF 
▪ Row: F1mass, F2mass or F3mass 
▪ Values: Count of ID 
where F1MF, F2MF and F3MF represent the molecular formula of the three most intense fragments; 
F1mass, F2mass and F3mass are related to the mass of each fragment and the ID corresponds to the number 
of entries on the database. For each fragment, a table containing the masses was created (see Appendix B), in 
green are illustrated the ones that were rectified and in red the ones not able to find. Thanks to a new feature 
integrated on the database, it was possible to type the fragment mass of a certain compound (e.g. nitracaine (1) 
was missing the molecular formulae of the first and second fragments – 150.0185 Da and 142.1589 Da, re-
spectively – Table 4.1) and click on the entry, its information is displayed. Then, we can look for the mass 
from a drop-down list, which comprises already the molecular formula associated to that specific fragment 
mass (Figure 4.3). 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 | Nitracaine (unknown): list of fragment masses and respective molecular formulae. 
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For modafinil (2), the molecular formula associated to F1mass was not available on the database, thus it 
was necessary to add it - mzCloudTM was used as an analytical support (Figure 4.4a). The F1mass, F2mass 
and F3mass of MMMP (3) were found from a drop-down list on the database (similar to the one depicted in 
Figure 4.3). The differences between dark red and blue values are slightly small. Likewise in modafinil, the 
F1mass of alfentanil (4) was absent; mzCloudTM provided the molecular formula that we were looking for 
(Figure 4.4b).  
 
Figure 4.4 | (a) Modafinil and (b) alfentanil: fragment ions (green circle) and their respective molecular formulae were 
obtained from mzCloudTM spectra. 
From (6) to (12), the molecular formulae were investigated with the support of mzCloudTM (Figure 4.5) 
and when not possible, we resorted to the fragmentation tools of ChemBioDraw Ultra 16.0. The latter one was 
applied to the compounds (5), (7), (8) and (11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 | (a) AB-CHMINACA, (b) benzylpiperazine, (c) PV8 and (d) UR-144 N-pentanoic acid: fragment ions (green 
circle) and their respective molecular formulae were obtained from mzCloudTM spectra. 
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In some cases, JWH-073-M-2-OH-Ind (7) and benzylpiperazine (9) for example, the mass discrepancy was 
considerable. Regarding the remaining compounds, the variations were not substantial; however, the imprecise 
values contribute to inaccurate interpretations (Table 4.1), therefore, it is fundamental to perform this step.  
Table 4.1 | List of compounds missing the fragment molecular formulae. The blue colour represents the right values, 
whereas the dark red corresponds to the non-accurate ones. 
 
Code 
 
Compound Drug class 
F1mass 
(table on the 
right) 
F2mass 
(table at the 
centre) 
F3mass 
(table on the 
left) 
1 Nitracaine unknown 
150.0186 
(150.0185) 
142.1589 - 
2 Modafinil unknown 152.0621   
3 MMMP cathinones 
165.0734 
(165.0732) 
88.0758 
(88.0757) 
128.1069 
(128.1070) 
4 Alfentanil opioids 
197.1285 
(197.1284) 
- - 
5 
CUMYL-PeGA-
CLONE 
cannabinoids 
255.1487 
(255.1492) 
- - 
6 AB-CHMINACA cannabinoids - 
312.9159 
(312.2070) 
- 
7 JWH-073-M-2-OH-Ind cannabinoids - 
326.1539 
(328.1332) 
. 
8 
PB-22-N-pentanoic 
acid 
cannabinoids - - 
101.0898 
(101.0597) 
9 Benzylpiperazine piperazine derivate - - 
161.0818 
(177.1386) 
10 PV8 cathinones - - 
189.1258 
(189.1274) 
11 AB-CHMINACA M1A cannabinoids - - 
239.1175 
(239.1179) 
12 
UR-144 N-pentanoic 
acid 
cannabinoids - - 
324.1955 
(324.1958) 
 
In order to have an insight into the number of compounds that hold fragment ions, a second pivot table 
was used. This table comprised the InChIKeys, molecular formulae of the three most intense peaks and re-
spective IDs. The following methodology was employed:  
▪ Filter: F1MF, F2MF and F3MF (considering the ones without their molecular formulae) 
▪ Row: InChIKey 
▪ Values: Count of ID 
We realised that roughly 21% (n=230) of the compounds on the database contained fragments, whereas 
79% (n=865) were still missing their fragments (Chart 4.1).  
 
865
230
No fragments
Fragments
Number of compounds
Chart 4.1 | Number of compounds containing fragments and no fragments in October 2018. 
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Approximately 61 systematic names (i.e. IUPAC names) of compounds on the database were also adjusted 
by using OPSIN and TiHKAL platforms. Of note, it is important to make sure that the substances correspond 
to the right IUPAC name, so that a valid InChIKey can be generated. The latter parameter is an identifier, 
characteristic of one specific chemical compound and allows its identification, which might be useful when 
searching for it on databases or websites. In addition, the compounds might be named in different manners as 
well as their systematic names can sometimes undergo a small number of variations, therefore the InChIKey 
is crucial for recognition of a substance.  
Nevertheless, in some situations it was not possible to find the proper IUPAC name, since there was not 
any InChIKey associated, which makes the investigation challenging, especially when we are dealing with 
isomers. There were two examples of compounds where it was not feasible to obtain the proper structures and 
therefore, their InChIKeys: JWH-073-2-Methyl and JWH-073-3-Methyl. The question is: where is the methyl 
group located? Is in tail, on the linked group? According to the available information on the database, we know 
that both substances belong to the cannabinoids class and have the following fragment ions: m/z 214.1226 and 
155.0491 (Table 4.2).  
Table 4.2 | Available information on the database for JWH-073-2-Methyl and JWH-073-3-Methyl. 
Compound RT PMF Pmass 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Origin 
Drug 
class 
LAB Method 
JWH-073-2-
Methyl 
12.31 C24H23NO 342.1852 
C11H7O 
155.0491 
C14H16NO 
214.1226 
- STD CB 
Uni. of 
Athens 
BPS 
JWH-073-3-
Methyl 
12.39 C24H23NO 342.1852 
C11H7O 
155.0491 
C14H16NO 
214.1226 
- STD CB 
Uni. of 
Athens 
BPS 
RT: Retention time, PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant frag-
ment ions, F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions, STD: Standard, CB: Cannabinoids, Uni. of Athens: University of 
Athens, BPS: Brukers Pesticide Screener. 
 
In this way, the starting point would be searching for JWH-073 on the Internet, like some drug websites 
(e.g. TiHKAL), in order to get a general chemical structure and try to make slight modifications by adding the 
methyl group in a more likely place (e.g. the tail). The potential structures were drawn by using ChemBioDraw 
Ultra 16.0 and the fragments were predicted by applying the fragmentation tools from the software (Figure 
4.6).  
Based on the fragmentation patterns, the initial assumption might be right, and both methyl groups may be 
placed on the unit corresponding to the tail. Afterwards the IUPAC name of each structure was attained, as 
well as the respective InChIKey. 
 
Figure 4.6 | Possible findings for JWH-073-2-Methyl and JWH-073-3-Methyl based on their fragmentation patterns (me-
thyl group in the tail). 
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The possibility of having the methyl group on the linked group (i.e. naphthalene ring) was also tested. 
However, we realised that the fragment ions did not match with the ones acquired (Table 4.3). Hence, we may 
conclude that the methyl group is positioned in the tail.  
Table 4.3 | Fragment ions for JWH-073-2-Methyl and JWH-073-3-Methyl with methyl group on the naphthalene ring. 
Compound 
Fragment ion 
tail + core + carbonyl group 
linked group + carbonyl group 
(methyl group on the naphthalene 
ring) 
JWH-073-2-Methyl 
200.1070 169.0648 
JWH-073-3-Methyl 
 
In case of plant-based substances, it was not possible to distinguish between two alkaloids such as, mi-
tragyna alkaloid 1 and mitragyna alkaloid (Paynantheine), since both present the same molecular formula and 
thus, identical molecular mass. Although the third fragment ion is distinct, it is not easy to similar proceed to 
the previous example (Table 4.4). 
Table 4.4 | Available information on the database for mitragyna alkaloid 1 and mitragyna alkaloid (Paynantheine). 
Compound RT PMF Pmass 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Origin 
Drug 
class 
LAB Method 
Mitragyna al-
kaloid 1 
7.54 C23H28N2O4 397.2122 
C11H12NO 
174.0913 
C12H18NO3 
224.1281 
C13H14NO 
200.1070 
STD P&E 
Uni. 
of 
Ath-
ens 
BPS 
Mitragyna al-
kaloid 
(Paynantheine) 
6.44 C23H28N2O4 397.2122 
C11H12NO 
174.0913 
C12H18NO3 
224.1281 
C13H17NO3 
235.1203 
STD P&E 
Uni. 
of 
Ath-
ens 
BPS 
RT: Retention time, PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant frag-
ment ions, F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions, STD: Standard, P&E: Plants & extracts, Uni. of Athens: University 
of Athens, BPS: Brukers Pesticide Screener. 
 
To conclude the validation process, 333 entries from EMCDDA and RESPONSE libraries were removed, 
since they were not contributing with valuable information. In other words, entries comprising only the exact 
parent mass, molecular formula, systematic name, InChIKey and drug class (non-experimental data) were de-
leted. Although, this was applied when more than one entry for the same compound was present, otherwise 
the entry would be kept on the database until a user includes that specific substance. For example, 5-IT (Table 
4.5) contained two additional entries encompassing the fragmentation ions (first and second rows, Table 4.5). 
It is possible to verify that an identical compound can have a variety of names (i.e. synonymous); therefore, 
the InChIKey is a key parameter for ensuring a proper differentiation between substances.  
Table 4.5 | Example of 5-IT and its two additional entries. 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Origin 
Drug 
class 
LAB InChIKey 
5-IT 
C11H14
N2 
175.1230    EMCDDA I CPH AUL-
GMISRJWGT
BA-UHFF-
FAOYSA-N 
 
5-(2-Aminopro-
pyl)indole 
C11H14
N2 
175.1230 
C9H8N 
130.0651 
C11H12N 
158.0964 
C8H7N 
117.0573 
STD I 
Uni. of 
Athens 
5-API 
C11H14
N2 
175.1230 
C9H8N 
130.0651 
C8H7N 
117.0573 
C11H12N 
158.0964 
STD I Adelaide 
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PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions, EMCDDA: European Monitoring Centre for Drugs and Drug Addiction, 
STD: Standard, I: Indolalkylamines, CPH: Copenhagen, Uni. of Athens: University of Athens. 
 
 
After completing the validation process, Australian, English and Finnish entries were included on the da-
tabase containing 193, 8 and 2 compounds, respectively.  
The emerging number of fentanyl analogues and synthetic cannabinoids on drug market forced us to create 
two sub-libraries that will be described below: fentanyl analogues fragment prediction (A) and synthetic can-
nabinoids fragment prediction (B), in order to understand the fragmentation patterns for both these drug clas-
ses. In this way, a list of compounds from each category was provided by the Section of Forensic Chemistry 
(Copenhagen, Denmark). The Chart 4.2 illustrates the exact amount: 51 fentanyl analogues and 215 synthetic 
cannabinoids, in comparison with the available methods on HighResNPS database. The fragmentation study 
was conducted based on articles and at the last stage, mzCloudTM was used to assure that the theoretical pre-
diction was on the right track, so that we could acquire the three most intense peaks. Before moving forward 
to the prediction, it is important to define the conditions on which the fragments ions were searched on 
mzCloudTM, since the collision gas (i.e. argon) employed on Xevo G2-S QTOF is different from the Orbitrap 
used on mzCloudTM (i.e. nitrogen). Hence, the intensity of the peaks might suffer some variations. We have 
noticed that 40 eV is more likely to provide akin outcomes. However, there might be some cases where this 
voltage is not available on mzCloudTM, thus 30 eV may be considered instead. We also need to make sure that 
we are looking at the correct ionization mode (i.e. ESI+).  
 
Chart 4.2 | Number of fentanyl analogues and synthetic cannabinoids (no method) used for fragment prediction, in com-
parison with the available entries on the database containing a method. 
 
A. Fentanyl analogues fragment prediction 
To carry out the fragmentation study for fentanyl analogues, a list of 51 substances were provided by the 
Section of Forensic Chemistry (compounds 1-51, Appendix C). In order to give an insight concerning the 
fragmentation routes for this class of drugs, their characteristic ions were determined based on their chemical 
structures. The common cleavages 143,144 are described below (Figure 4.7) and a supplemental material com-
prising the theoretical fragment ions for each compound can be found on Appendix D. 
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Fragment a (Figure 4.7 and Appendix D) 
This fragment corresponds to the degradation of the amide functional group through the breakdown of the 
nitrogen and carbonyl carbon bond. The phenomenon is observed for a certain number of compounds such as, 
4-fluorobutyrfentanyl (10) with a m/z value 299.1918 (C19H24FN2+), β-hydroxythiofentanyl (23) with a m/z 
value 285.1420 (C17H21N2S+), butyryl fentanyl (25) and isobutyryl fentanyl (38) with a m/z value 281.2012 
(C19H25N2+).  
 
Fragment b (Figure 4.7 and Appendix D) 
This fragment is the result of breaking the amide moiety bond and the piperidine ring. In case, the fentanyl 
analogues do not hold any substituent in the phenethyl group, it is possible to observe the formation of a 
Figure 4.7 | Proposed fragmentation pathways for fentanyl analogues (Appendix D). 
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carbocation with a m/z value 188.1434 (C13H18N+). The obtained fragment may be subjected to a consecutive 
disruption between the alpha-carbon and the piperidine ring, giving rise to m/z 105.0699 (C8H9+, fragment 
b2). Both fragments are detected in the following fentanyl analogues: 2-fluoro acrylfentanyl (1), 2-fluorobu-
tyryl fentanyl (2), 2-fluoroisobutyryl fentanyl (3), 2-methoxy butyryl fentanyl (4), 3-fluoro methoxyacetyl fen-
tanyl (5), 3-fluorofentanyl (6), 3-fluoroisobutyryl fentanyl (7), 4-fluoro acrylfentanyl (9), 4-fluorofentanyl 
(11), acrylfentanyl (16), benzodioxole fentanyl (20), cyclobutyl fentanyl (31), cyclohexyl fentanyl (32), cyclo-
propyl fentanyl (33), despropionyl 3-fluorofentanyl (34), despropionyl p-fluoro fentanyl (35), FIBF (36), meth-
oxyacetyl fentanyl (40), m-fluorofentanyl (42) and ocfentanil (46). The previous values may suffer slight mod-
ifications depending on the type of moiety attached to the piperidine ring. In this sense, we have noticed that: 
1. butyryl norfentanyl (26), isobutyryl norfentanyl (39), methoxyacetyl norfentanyl (41) and norfentanyl 
(45) lead to a product ion with m/z 84.0808 (C5H10N+), which comprehend a hydrogen linked to the 
piperidine ring, instead of a phenethyl group;  
2. benzylfentanyl (22) results in a fragment ion with m/z 174.1277 (C12H16N+) that is characteristic of 
substances comprising a benzyl group;  
3. thiofentanyl (50) originates a fragment with m/z 194.0998 (C11H16NS+), which consists of replacing a 
phenethyl for a thienylethyl group;  
4. 3-methylfentanyl (8), 4-methyl fentanyl (13), α-methyl butyryl fentanyl (17), α-methylacetylfentanyl 
(19), β-methylfentanyl (24), cis-3-methyl butyryl fentanyl (28) and cis-mefentanyl (30) generate an 
ion with m/z  202.1590 (C14H20N+), which contain a methyl group on the piperidine ring (for 6,28 and 
30), at the alpha-carbon position (for 17 and 19), in the phenyl group (for 13, 28 and 30) or at the beta-
carbon position (for 24); 
5. α-methyl thiofentanyl (18) and cis-3-methylthiofentanyl (29) produce a fragment with m/z 208.1154 
(C12H18NS+) that present a methyl group at the alpha-carbon position or on the piperidine ring and a 
thienylethyl group linked to it, respectively;    
6. ohmefentanyl (47) gives rise to a product ion with m/z 218.1539 (C14H20NO+) that corresponds to a 
methyl group on the piperidine ring and a hydroxyl group at the beta-carbon position; 
7. sufentanil (49) leads to a fragment with m/z 238.1260 (C13H20NOS+), which is related to a methox-
ymethyl group on the piperidine ring and a thienylethyl group attached to it; 
8. carfentanil (27) promotes the formation of an ion with m/z 246.1489 (C15H20NO2+), this one involves 
the presence of a carboxylate group on the piperidine ring and the phenethyl group linked to it.  
Regarding the fragment b2 (Figure 4.7 and Appendix D), it is important to underline that compounds 
containing a thienylethyl group attached to the piperidine ring are more likely to induce the generation of an 
ion with m/z 111.0263 (C6H7S+). In addition, some product ions with m/z 202.1590 may undergo a subsequent 
fragmentation leading to a minor fragment ion (m/z 119.0855, C9H11+). Moreover, substances holding a benzyl 
group linked to the piperidine ring may result in a carbocation with m/z 91.0542 (C7H7+).  
 
Fragment c (Figure 4.7 and Appendix D) 
This fragment is produced due to the prior fragment. In other words, the product ion losses a carbonyl 
oxygen and therefore, it experiences dehydration, which brings about the fragment termed c2. The fragment c 
is observed for butyryl norfentanyl (26) and isobutyryl norfentanyl (39) with a m/z value 164.1070 
(C10H14NO+), acetyl norfentanyl (15) with a m/z value 136.0757 (C8H10NO+), methoxyacetyl norfentanyl (41) 
with a m/z value 166.0863 (C9H12NO2+) and norfentanyl (45) with a m/z value 150.0913 (C9H12NO+). A further 
fragmentation generates the following m/z values: 341.1682 (C20H25N2OS+) for β-hydroxythiofentanyl (23) 
and 134.0964 (C9H12N+) for ohmefentanyl (47), which correspond to fragment c2, as mentioned previously.  
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Fragment d (Figure 4.7 and Appendix D) 
This fragment involves the degradation of the piperidine ring owing to the cleavage on both C(2)-N and 
C(6)-N, which promotes the formation of specific m/z values relying on possible substituents on N-benzene 
group and carbonyl of the amide functional group such as, 232.1132 (C14H15FNO+) for 2-fluoro acrylfentanyl 
(1), 250.1238 (C14H17FNO2+) for 3-fluoro methoxyacetyl fentanyl (5), 248.1445 (C15H19FNO+) for 4-fluoro-
butyrfentanyl (10),  260.1645 (C16H22NO2+) for 4-methoxy-butyryl fentanyl (12), 202.1226 (C13H16NO+) for 
acetyl norfentanyl (15), 228.1383 (C15H18NO+) for cyclopropyl fentanyl (33), 230.1539 (C15H20NO+) for iso-
butyryl fentanyl (38) and 244.1696 (C16H22NO+) for valeryl fentanyl (51).  
 
In order to make sure, that the proposed fragmentation might be applied to future analogues, three com-
pounds from the fentanyls list were selected without any criteria and thereafter, compared with the entries 
available on HighResNPS. In this way, acetyl norfentanyl (15), FIBF (36) and valeryl fentanyl (51) were ana-
lysed. For the first example (compound 15, Table 4.6), it is observed that the first product ions match between 
the three users, regarding the second one is not possible to define the right value; we would need the data from 
Aarhus to ensure a proper interpretation and the third fragment does not allow us to get any further details 
regarding the fragmentation. Although the peak intensity is not similar, it presents an identical value to one of 
the second fragments. Thus, we may conclude that they agree at least in two fragments.  
 
Table 4.6 | First example: acetyl norfentanyl. 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF   
F2mass 
F3MF 
F3mass 
Origin LAB Method 
Acetyl 
norfentanyl 
C13H18N2O 219.1492 
C5H10N 
84.0808 
C13H16NO 
202.1226 
C8H10NO 
136.0757 
TRT CPH FAFP 
C5H10N 
84.0808 
C8H10NO 
136.0757 
- STD CPH WFTS  
C5H10N 
84.0808 
- - STD Aarhus Bruker 3 
PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions, TRT: Theoretical, STD: Standard, CPH: Copenhagen, FAFP: Fentanyl 
Analogues Fragment Prediction, WFTS: Waters Forensic Toxicology Screening. 
 
Concerning the second example (compound 36, Table 4.7), the first fragments fit with all laboratories. In 
terms of the second fragments, two out of one are consistent. Nevertheless, the third one does not provide any 
additional information.  
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Table 4.7 | Second example: FIBF. 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF   
F2mass 
F3MF 
F3mass 
Origin LAB Method 
FIBF C23H29FN2O 369.2337 
C13H18N 
188.1434 
C8H9 
105.0699 
C15H19FNO 
248.1445 
STD CPH WFTS  
C13H18N 
188.1434 
- - Seizure Aarhus Bruker 3 
C13H18N 
188.1434 
C8H9 
105.0699 
- TRT  CPH FAFP  
C13H18N 
188.1434 
C19H24FN2 
299.1918 
- LIB CPH TF QExactive 1 
PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions, STD: Standard, TRT: Theoretical, LIB: Library, CPH: Copenhagen, WFTS: 
Waters Forensic Toxicology Screening, FAFP: Fentanyl Analogues Fragment Prediction. 
 
For the last example (compound 51, Table 4.8), the first and third fragments are compatible, while the 
second ones generate dissimilar values.  
Table 4.8 | Third example: valeryl fentanyl. 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF   
F2mass 
F3MF 
F3mass 
Origin LAB Method 
Valeryl fen-
tanyl 
C24H32N2O 365.2587 
C13H18N 
188.1434 
C19H25N2 
281.2012 
C16H22NO 
244.1696 
TRT CPH FAFP 
C13H18N 
188.1434 
C8H9 
105.0699 
C16H22NO 
244.1696 
STD CPH WFTS  
PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions, TRT: Theoretical, STD: Standard, CPH: Copenhagen, FAFP: Fentanyl 
Analogues Fragment Prediction, WFTS: Waters Forensic Toxicology Screening. 
 
Based on this study, we might deduce that the predicted fragmentation may assist the analyst in interpreting 
most of the generated product ions within the fentanyls drug class, giving an insight into an array of substances. 
In addition, the first fragments coincide always with the data reported by other laboratories and, to a lesser 
extent, second and third fragment ions. Hence, the fragmentation pathways can be applied to future analogues, 
since it provides an overview concerning the type of fentanyls that we are dealing with. Moreover, it is possible 
to notice that according to their chemical structure, they may adopt a similar fragmentation pattern, which is 
especially useful when analysing novel compounds, since they are characterised by minor modifications in 
their skeleton.  
 
B. Synthetic cannabinoids fragment prediction 
To conduct the fragmentation study for synthetic cannabinoids, a list containing 215 compounds were 
culled from the Section of Forensic Chemistry (compounds 1-215, Appendix E). In order to give a compre-
hensive overview regarding the fragmentation patterns among this class of drugs, they were divided into sub-
groups according to their chemical structures, as suggested by K. Sekuła et al.: Analysis of Fragmentation 
Pathways of New-Type Synthetic Cannabinoids Using Electrospray Ionization  44:  
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▪ B.1 SCs with adamantly ring 
▪ B.2 SCs with naphthalene or quinoline ring  
▪ B.3 SCs with 2,2,3,3-tetramethylcyclopropyl (TMCP) moiety  
▪ B.4 PINACA-SCs 
▪ B.5 FUBINACA-SCs 
▪ B.6 CHMINACA-SCs 
▪ B.7 Other SCs 
 
B.1 SCs with adamantly ring (Appendix F) 
Compounds holding an adamantly ring as the linked group were more likely to give rise to an ion with a 
theoretical m/z value of 135.1168, which corresponds to the most intense peak in the MS/MS spectrum 
(mzCloudTM), thus it is considered a characteristic ion for synthetic cannabinoids containing this type of ring. 
In addition, ions with the following m/z values: 98.0964 and 112.1121 (for AM1248 (73)), 214.1226 (for JWH 
018 adamantyl carboxamide (112)), 243.1128 (for ATHPINACA isomer 2 (85)) and 284.1645 (for SER-601 
(192)) were also observed. The previous fragments were associated with the core of SCs combined with a 
linker and a tail section. However, for AM1248 (73) the fragment ions corresponded merely to the tail section. 
Of note, these SCs may consist of a pair of aryl groups attached to a carbonyl or carboxyamide function and 
the core might be either an indole (R1, R3 = -CH) or an indazole (R1, R3 = -N) moiety. For both cases, the 
fragmentation pathways are illustrated in Figure 4.8. It is important to highlight that SER-601 (192) contains 
a 4-hydroxyquinoline on its core instead, nevertheless the fragmentation pattern is identical since it comprises 
an adamantly ring and a carboxyamide linker.    
From a chemical point of view, the groups bonded to the carboxyamide and carbonyl functions can be 
easily broken. In this specific situation, the dominant ion corresponds to the fragments a and c, respectively 
(Figure 4.8). The remaining part of the molecule is not always visible in the MS/MS spectrum. Moreover, the 
m/z values may differ according to the substituents R1, R2, R3 and R4, as well as the core considered (e.g. indole 
and indazole).  
 
Figure 4.8 | Fragmentation pathways for SCs with adamantly ring: carboxyamide function (scheme A) and carbonyl 
function scheme B) (Appendix F). 
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B.2 SCs with naphthalene or quinoline ring 
This sub-group consists of compounds containing three possible linker groups i.e. carbonyl, carboxyamide 
and carboxyl moiety, which will be mentioned in more detail below. In this way, the linker will determine the 
characteristic fragment ions obtained.   
 
• with carbonyl group (Appendix G) 
These SCs contain a naphthalene ring combined with a core section, which can be either an indole or inda-
zole via a carbonyl group. It is worth noting that, other types of cores might be observed, however they are 
less frequent than the aforementioned moieties. All the analysed compounds comprised a naphthalene ring 
instead of a quinoline as the linked group. The fragmentation pattern is defined by the following rational: the 
oxygen bounded to the carbon atom (i.e. linker) and the nitrogen present in the indole/indazole ring might be 
the primary sites of protonation 145. Nevertheless, the oxygen atom is more basic compared to the nitrogen 
atom, since the latter one is doubly conjugated with an aromatic ring. In this way, the C-C bonds adjacent to 
the oxygen atom are easily cleaved, which may produce two typical product ions 145, denoted as fragment a 
and fragment b in Figure 4.9. The first fragment a coincided to naphthoyl cation. If the naphthalene ring is 
unsubstituted, the generated ions will correspond to 155.0491 (C11H7O+, fragment a) and the fragment b may 
lead to a determined value that relies on R2 R3 and R4. In other words, for the latter fragment its values will be 
dictated by the chemical composition of each substituent. It is important to remember that the m/z values will 
be different according to the core.  
 
Figure 4.9 | Proposed fragmentation pathways for SCs containing a naphthalene ring and a carbonyl group (Appendix 
G). 
Some examples of the investigated compounds were used to elucidate the common fragment ions for two 
specific cores moieties:  
1. indole (R2 = -CH) (Appendix G) 
Formation of characteristic ions of the indole ring: m/z 144.0444 (for 1-naphthoyl indole (1)), 189.0295 and 
277.0983 (for AM1235 (71)), 232.1132 (for Cl2201 (90)), 109.0448 and 252.0819 (for FUB-JWH 018 (103)), 
242.1539 (for JWH 020 (117)), 212.1070 (for JWH 022 (118)), 172.0757 (for JWH 071 (119)), among others. 
2. indazole (R2 = -N) (Appendix G) 
Formation of characteristic ions of the indazole ring: m/z 145.0396 and 213.1022 (e.g. 5-bromo THJ 018 
(9)). 
As mentioned previously, there are some compounds that do not contain any of the prior cores such as, EG-
018 (95). Nonetheless, the applied fragmentation rules can still be employed. In this sense, the fragment ion 
corresponding to the linker and core section (i.e. a carbazole) will be 264.1383 (fragment b).   
On the other hand, if the naphthalene ring contains substituents, the product ion corresponding to fragment 
a will differ. Thus, the presence of an alkyl group such as, a methyl, ethyl, propyl will give rise to 169.0648 
(e.g. JWH 073 4-methylnaphthyl analog (123)), 183.0804 (e.g. JWH-210 (148)) and 197.0961 (e.g. JWH-180 
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(144)), respectively. In case of replacement of a hydrogen for a methoxy group, the following ion is formed: 
185.0597 (e.g. JWH 080 (127)). In addition, a bromo, chlorine or fluorine substituent is also evident and the 
characteristic ions for both halogens are registered at m/z 232.9597 (e.g. JWH 387 (133)), 189.0102 (e.g. JWH-
398 (150)) and 173.0397 (JWH 412 (134)), respectively.      
  
• with carboxyl group (Appendix H) 
These SCs comprises a naphthalene or quinoline ring combined with a core section, which can be either an 
indole or indazole moiety via a carboxyl group. The investigated compounds contained almost an equal number 
of naphthalene (R1 = -CH) and quinolone (R1 = -N) rings as part of the linked group. In terms of fragmentation, 
it was not observed a product ion (i.e. fragment a) that could correspond to the rings. As far as we know, any 
article has reported an explanation concerning this phenomenon. In this way, for all the analysed substances, 
the MS/MS spectra on mzCloudTM have shown no records associated to the carboxyl cleavage, which allowed 
to prove that the information above was valid. Based on this, the fragment ions were predicted without con-
sidering the prior bond break (Figure 4.10). Therefore, we should focus merely on the fragment b, which may 
present an array of characteristic ions depending on the chemical structure of the substituents. It is important 
to notice that two main core sections can appear such as, indole (R2 = -CH) and indazole (R2 = -N) (Figure 
4.10). Hence, some of the following product ions may be generated: m/z 144.0444 and 232.1132 (for 5-fluoro 
PB-22 (35) and NM-2201 (177)), 144.0444 and 214.1226 (for CBL-018 (88)), lastly 97.1012, 144.0444 and 
240.1383 (for QUCHIC (187)) for indole. On the other hand, 213.1022 and 251.1190 (for 5-fluoro NPB-22 
(34)) and, 145.0396, 215.1179 and 233.1285 (for SDB-005 (191)) for indazole. Furthermore, four of the afore-
mentioned compounds contained a naphthalene ring, CBL-018 (88), NM-2201 (177), QUCHIC (187), SDB-
005 (191), whereas the remaining two a quinolone ring, 5-fluoro NPB-22 (34) and 5-fluoro PB-22 (35). 
 
Figure 4.10 | Proposed fragmentation pathways for SCs containing a naphthalene/quinoline ring and a carboxyl group  
(Appendix H). 
  
• with carboxyamide group (Appendix I) 
These SCs differ in the linking group i.e. carboxyamide. Likewise in the previous two-linker groups, these 
compounds may consist of a core section, which can be either an indole or indazole as well as a linked group 
that will be a naphthalene (R1 = -CH) or quinolone ring (R1 = -N). In light of above, the fragment a is not 
registered in MS/MS spectra on mzCloudTM, not even on research articles regarding the topic (Figure 4.11). 
Thus, the fragment b will be the only considered. However, it is important to highlight that the m/z values 
will suffer some variations due to the chemical composition of the substituents R2 and R3. The following char-
acteristic ions can be obtained: m/z 144.0444 and 214.1226 (for JWH 018 8-quinolinyl carboxamide (110) and 
NNEI (178)) for an indole ring, whereas m/z 145.0396 (for NNEI 2-indazole isomer (179)), 145.0396 and 
215.1179 (for MN-18 (175)) and 213.1022 and 233.1085 (for 5-fluor MN-018 (32) and 5-fluor THJ (40)) for 
an indazole ring. From the prior compounds, only two contained a quinoline ring, 5-fluor THJ (40) and JWH 
018 8-quinolinyl carboxamide (110), all the others presented a naphthalene ring.  
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Figure 4.11 | Proposed fragmentation pathways for SCs containing a naphthalene/quinoline ring and a carboxyamide 
group (Appendix I). 
 
B.3 SCs with 2,2,3,3-tetramethylcyclopropyl (TMCP) moiety (Appendix J) 
Compounds comprising a TMCP moiety as part of the linked group are more likely to generate a fragment 
ion with a m/z value 125.0961 (fragment a), which corresponds to the cleavage of the bond adjacent to the 
carbonyl function. It is also verified a product ion associated with the TMCP only (m/z 97.1012, fragment b). 
Depending on the core and tail section chemical composition, it is possible to obtain different m/z values such 
as, 257.1285 (for A-796260 (44)), 242.1176 (for A-834735 (46)), 242.1414 (for AB-005 (49)), 233.1085 (for 
FAB-144 (99)), 252.0819 (for FUB-144 (102)), 214.1226 (for UR-144 (198)), 244.0968 (for UR-144 5-pen-
tanoic acid metabolite (199)), 248.0837 (for UR-144 N-(2-chloropentyl) analog (201)), 292.0332 (for UR-144 
N-(5-bromopentyl) analog (204)), 242.1539 (for UR-144 N-(5-methylhexyl analog (206) and UR-144 N-heptyl 
analog (207)), 232.1132 (for XLR-11 (211)), 248-1081 (for XLR-11 N-(4-hydroxypentyl) metabolite (213)), 
212.1070 (for XLR-11 N-(4-pentenyl) analog (214)) and 254.0787 (for XLR-12 (215)), which correspond to 
fragment c, whereas 187.0900 (for A-836339 (48)) is related to fragment d, as illustrated in Figure 4.12. In 
addition, some of the aforementioned substances can still suffer fragmentation, giving rise to the following m/z 
values: 114.0913 (for A-834735 (46)), 112.1121 (for AB-005 (49)), 213.1022 (for FAB-144 (99)), 109.0448 
(for FUB-144 (102)) and 55.0542 (for azidoindolene 1 (86)) is the only associated to fragment e. The first 
ions are formed by the disruption of the bond between the TMCP moiety and carbonyl group, whereas the 
second ones represent a subsequent fragmentation of the previous product ions, which occurs in the tail section. 
It is commonly observed the removal of a fluorine atom at the end of the tail and the bond breaking of a 
fluorobenzyl (e.g. compound 102) or morpholinoethyl group (e.g. compound 44) from the core section.    
 
RESULTS AND DISCUSSION 
44 
 
 
Figure 4.12 | Proposed fragmentation pathways for SCs with a TMCP moiety (Appendix J). 
 
B.4 PINACA-SCs (Appendix K) 
These SCs are characterized by an indazole ring with a pentyl chain and a carboxamide linker. For these 
compounds the following main ions might be generated (Figure 4.13): fragment a corresponds to the loss of 
a NH2 group. All the substances containing an amide moiety may result in m/z 332.1769 (for 5-fluoro AB-
PINACA (14)), m/z 346.1925 (for 5-fluoro ADB-PINACA (18), 5-fluoro ADB-PINACA isomer 2 (19) and 5-
fluoro-2-ADB-PINACA isomer 2 (41)) and m/z 328.2020 (for ADB-PINACA (67)). while m/z 213.1022 and 
m/z 233.1085 are associated to fragments b and c, respectively. Both are registered for 5-fluoro AB-PINACA 
(14), 5-fluoro ADB-PINACA (18) and 5-fluoro ADB-PINACA isomer 2 (19). Of note, the first value (frag-
ment b) is associated with the loss of a fluorine atom and the second one (fragment c) is derived from the C-
N cleavage of the amide group. In addition, when the pentyl chain does not comprise a halogen (R3) at the end 
of the chain, it is possible to observe a m/z value of 215.1179 for ADB-PINACA (67) and CUMYL-PINACA 
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(92). In case of substances containing a CUMYL moiety (5F-CUMYL-PINACA (12) and CUMYL-PINACA 
(92)), their linked group (i.e. isopropylbenzene/cumyl) differ from the previous ones. Therefore, the m/z values 
will be: 119.0855 and 91.0542 (fragment a). The latter fragment ion is formed by the cleavage between the 
isopropyl and benzene. 
 
 
B.5 FUBINACA-SCs (Appendix L) 
The FUBINACA sub-group is composed by a fluorobenzyl group that makes part of the tail section, an 
indazole ring and carboxamide linker. These compounds exhibited a common fragmentation pattern (Figure 
4.14). It was observed that the C-N cleavage of the amide group would result in fragment b with a m/z value 
253.0772. Further fragmentation of this ion led to the formation of 109.0448, which is attributed to the disso-
ciation of the bond between the core (i.e. indazole ring) and the fluorobenzyl group. These product ions were 
registered for ADB-FUBINACA (65), APP-FUBINACA (83), EMB-FUBINACA (97), MDMB-FUBINACA 
(167) and MMB-FUBINACA (174). For three compounds, it was possible to notice the cleavage of the bond 
between the carbonyl group and the carbon attached to R2, which formed the following ions: m/z 352.1456 (for 
EMB-FUBINACA (97)), m/z 338.1663 (for MDMB-FUBINACA) and m/z 324.1507 (for MMB-FUBINACA 
(174)). This fragment corresponds to the loss of an ester group. In addition, compounds comprising an amide 
moiety are more likely to loss a NH2 group giving rise to fragment a. The mass values will vary according to 
the chemical composition of substituent R2: m/z 366.1612 (for ADB-FUBINACA (65)) and m/z 400.1456 (for 
APP-FUBINACA (83)). 
 
Figure 4.14 | Proposed fragmentation pathways for FUBINACA compounds (Appendix L).  
 
 
Figure 4.13 | Proposed fragmentation pathways for PINACA compounds (Appendix K). 
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B.6 CHMINACA-SCs (Appendix M) 
These type of SCs consist of a cyclohexylmethyl group in the tail section, an indazole as a core and a 
carboxamide linker. For CHMINACA, it is possible to distinguish two characteristic ions with m/z values 
241.1335 (fragment b) and 145.0396 (fragment c), both illustrated in Figure 4.15. The first one corresponds 
to the C-N cleavage of the amide group, which was detected for the following compounds: AB-CHMINACA 
(52), AB-CHMINACA metabolite M2 (56), AB-CHMINACA metabolite M6 (59), APP-CHMINACA (82), 
MAB-CHMINACA (153), MAB-CHMINACA metabolite M10 (155), MA-CHMINACA (160), MDMB-
CHMINACA (166) and MO-CHMINACA (176). In other words, this fragment is derived from the core (i.e. 
indazole) combined with the carbonyl group and cyclohexylmethyl moiety. A subsequent fragmentation led to 
the fragment c, which is related to the dissociation of the cyclohexylmethyl moiety from the core of the mol-
ecule. In addition, some substances have shown the dissociation of bond between the carbonyl group and the 
carbon attached to R1 giving rise to fragment a with m/z values: 340.2020 (for AB-CHMINACA (52) and 
AB-CHMINACA 2-indazole isomer (53)), 388.2020 (for APP-CHMINACA (82)) 354.2227 (for MAB-
CHMINACA (153)) and 370.2125 (for MAB-CHMINACA metabolite M1 (154)), which depend on R1 sub-
stituents. In the case of methoxy groups, the product ions generated might be: m/z 312.2070 (for MA-
CHMINACA (160)) and m/z 323.2227 (for MDMB-CHMINACA (166)).  
 
Figure 4.15 | Proposed fragmentation pathways for CHMINACA compounds. (Appendix M). 
 
B.7 Other SCs  
Some compounds on the list do not fit into any of the aforementioned sub-groups. However, no matter their 
chemical structure they may present similar fragmentation patterns, which will be briefly described below. 
Three substances were used to elucidate the fragmentation: 5-fluoro PY-PICA (37), ADBICA (66) and 
MDMB-CHMICA (165). In order to simplify the analysis, their structures and respective fragmentation path-
ways are depicted in Figure 4.16. In Figure 4.161a, it is possible to observe that the bonds adjacent to the 
carbonyl group will be cleaved giving rise to two main ions with m/z values: 98.0600 (fragment a), which 
corresponds to the linked group and linker and 232.1132 (fragment b) that is related to the linker, core and 
tail section. The latter one undergoes further fragmentation leading to fragment c, which is the result of dis-
sociation of the tail section from the core with subsequent elimination of a fluorine atom. The fragment b is 
common to some SCs containing a naphthalene ring such as, 5-fluoro PB-22 ((35), Appendix H), Cl2201 
((90), Appendix G) and NM-2201 ((177), Appendix H).  
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Figure 4.16 | Proposed fragmentation pathways for three compounds that do not fit into any of the aforementioned sub-
groups: (a) 5-fluoro PY-PICA, (b) ADBICA and (c) MDMB-CHMICA.  
For ADBICA (Figure 4.16b), it is noticed that the bond between the C and N atoms is more likely to break 
forming an ion with m/z value 214.1226 (fragment a). This ion might also be fragmented generating the frag-
ment b (144.0444), which is due to the cleavage of the bond between the core and the tail section. Regarding 
the last example (Figure 4.16c), the C-N cleavage of the amide group is observed and thus, the fragment a is 
formed. Afterwards, the disintegration of the core from the tail section is detected. In this way, two ions may 
be obtained 144.0444 and 97.1012 that correspond to fragments b and c, respectively. The m/z value 144.0444 
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is shared by an array of compounds from the list such as, 1-naphthoyl indole ((1), Appendix G), 5-fluoro PB-
22 ((35), Appendix H) and NM-2201 ((177), Appendix H). In addition, 214.1226 is also prevalent in other 
substances like, CBL-018 ((88), Appendix H) and JWH 018 8-quinolinyl carboxamide ((110), Appendix I).   
In order to investigate the effectiveness of the described SCs fragmentation, one compound belonging to 
each of the aforementioned sub-groups was selected from the HighResNPS database and its fragment ions 
were further compared to the fragmentation available from other laboratories. We started with SCs containing 
an adamantly group. For this case, the substance JWH 018 adamantyl carboxamide (112) was elected. On the 
database, there was only one entry from Labor Krone (DE) (Table 4.9). It is possible to conclude that the 
German laboratory agrees with the first two fragments and includes a third product ion (i.e. 144.0444), which 
was not observed for the method SCFP. However, the predicted fragmentation matched well (i.e. two frag-
ments out of three).  
Table 4.9 | Example for SCs containing an adamantly group: JWH 018 adamantly carboxamide. 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF   
F2mass 
F3MF 
F3mass 
Origin LAB Method 
JWH 018 ada-
mantly carbox-
amide 
C24H32N2O 365.2587 
C10H15 
135.2268 
C14H16NO 
214.1226 
C9H6NO 
144.0444 
STD 
Labor 
Krone 
WFTS 
C10H15 
135.2268 
C14H16NO 
214.1226 
- TRT CPH SCFP 
PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions, STD: Standard, TRT: Theoretical, CPH: Copenhagen, WFTS: Waters Fo-
rensic Toxicology Screening, SCFP: Synthetic Cannabinoid Fragment Prediction. 
For the second sub-group, a compound comprising a naphthalene ring was chosen (e.g. JWH-210 (148)). 
In Table 4.10, it is illustrated its fragment ions reported in two more methods (BPS and Thermo 2). In com-
parison with the theoretical fragmentation (i.e. method SCFP), the product ions were compatible (i.e. two 
fragments out of two).  
Table 4.10 | Example for SCs comprising a naphthalene ring: JWH-210. 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF   
F2mass 
F3MF 
F3mass 
Origin LAB Method 
JWH-210 C26H27NO 370.2165 
C13H11O 
183.0804 
C14H16NO 
214.1226 
- TRT CPH SCFP 
C13H11O 
183.0804 
C14H16NO 
214.1226 
- STD Uni. of Athens BPS 
C13H11O 
183.0804 
C14H16NO 
214.1226 
- STD CPH Thermo 2 
PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions, TRT: Theoretical, STD: Standard, CPH: Copenhagen, Uni. of Athens: Uni-
versity of Athens, SCFP: Synthetic Cannabinoid Fragment Prediction, BPS: Brukers Pesticide Screener. 
In case of SCs with a TMCP moiety, UR-144 (198) was considered (Table 4.11). It was verified that all 
the laboratories agreed in the first fragment and in general, they assented to the second product ion, except the 
Labor Krone. Regarding the last fragment, there was no coherence between users. Nevertheless, we may con-
clude that at least two ions coincide and thus, they corresponded to the predicted fragmentation (i.e. method 
SCFP).  
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Table 4.11 | Example of SCs with a TMCP moiety: UR-144. 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF   
F2mass 
F3MF 
F3mass 
Origin LAB Method 
UR-144 C21H29NO 312.2322 
C8H13O 
125.0961 
C7H13 
97.1012 
C14H16NO 
214.1226 
STD 
Labor 
Krone 
WFTS 
C8H13O 
125.0961 
C14H16NO 
214.1226 
- STD 
Ade-
laide 
Agilent 1 
C8H13O 
125.0961 
C14H16NO 
214.1226 
- STD 
Uni. of 
Athens 
BPS 
C8H13O 
125.0961 
C14H16NO 
214.1226 
C9H6NO 
144.0444 
STD 
RCMP-
NFLS 
WFTS 
C8H13O 
125.0961 
C14H16NO 
214.1226 
C7H13 
97.1012 
TRT CPH SCFP 
PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions, STD: Standard, TRT: Theoretical, Uni. of Athens: University of Athens, CPH: 
Copenhagen, WFTS: Waters Forensic Toxicology Screening, BPS: Brukers Pesticide Screener SCFP: Synthetic Cannabinoid Fragment Prediction. 
5F-CUMYL-PINACA (12), which makes part of substances with a PINACA acronym, shared the first 
fragment with Adelaide; however, Aarhus did not consider the same fragment ion. In addition, the second 
product ion did not suffer any modification. In relation to the last one, there was not an agreement between the 
laboratories (Table 4.12).  
Table 4.12 | Example from PINACA sub-group: 5F-CUMYL-PINACA. 
PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions, STD: Standard, TRT: Theoretical, R: RESPONSE, CPH: Copenhagen, SCFP: 
Synthetic Cannabinoid Fragment Prediction. 
Concerning the FUBINACA acronym, ADB-FUBINACA (65) was the selected compound. It was noticed 
that the fragment ions were completely in concordance with the theoretical fragmentation (Table 4.13). Alt-
hough, it was not observed a third product ion.  
 
 
 
 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF   
F2mass 
F3MF 
F3mass 
Origin LAB Method 
5F-CUMYL-
PINACA 
C22H26FN3O 368.2132 
C13H14FN2O 
233.1085 
C9H11 
119.0855 
C13H17FN3O 
250.1350 
STD Adelaide Agilent 1 
C13H14FN2O 
233.1085 
C9H11 
119.0855 
C13H13N2O 
213.1022 
TRT CPH SCFP 
C13H17FN3O 
250.1350 
- - R Aarhus Bruker 3 
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Table 4.13 | Example from FUBINACA sub-group: ADB-FUBINACA. 
PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions, TRT: Theoretical, STD: Standard, CPH: Copenhagen, Uni. of Athens: Uni-
versity of Athens, SCFP: Synthetic Cannabinoid Fragment Prediction, WFTS: Waters Forensic Toxicology Screening. 
For the CHMINACA acronym, AB-CHMINACA (52) subjected to the fragmentation analysis. Most of the 
obtained fragment ions were conformed to the predicted fragmentation, especially the first and second ions. 
Even though, the Labor Krone has considered a different intensity order. Some laboratories suggested the 
presence of more than two fragments (Table 4.14).  
Table 4.14 | Example from CHMINACA sub-group: AB-CHMINACA. 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF   
F2mass 
F3MF 
F3mass 
Origin LAB Method 
AB-
CHMINACA 
C20H28N4O2 357.2285 
C15H17N2O 
241.1335 
C19H26N3O 
312.2070 
- STD 
Ade-
laide 
Agilent 1 
C15H17N2O 
241.1335 
C19H26N3O 
312.2070 
- TRT CPH SCFP 
C15H17N2O 
241.1335 
C19H26N3O 
312.2070 
C8H5N2O 
145.0396 
STD 
Uni. of 
Athens 
BPS 
C15H17N2O 
241.1335 
C8H5N2O 
145.0396 
C19H26N3O 
312.2070 
STD 
Labor 
Krone 
WFTS 
C15H17N2O 
241.1335 
C19H26N3O 
312.2070 
- R Aarhus Bruker 3 
PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions, STD: Standard, TRT: Theoretical, R: RESPONSE, CPH: Copenhagen, Uni. 
of Athens: University of Athens, SCFP: Synthetic Cannabinoid Fragment Prediction, BPS: Brukers Pesticide Screener, WFTS: Waters Forensic Toxi-
cology Screening. 
Lastly but not least, substances that do not fit into any of the prior sub-groups such as, 5-fluoro PY-PICA 
(37). In this case, the first two product ions accorded between each other, but this did not apply to the third 
fragment, the values were divergent (Table 4.15).  
 
 
 
 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF   
F2mass 
F3MF 
F3mass 
Origin LAB Method 
ADB-FUBI-
NACA 
C21H23FN4O2 383.1878 
C15H10FN2O 
253.0772 
C7H6F 
109.0448 
- TRT CPH SCFP 
C15H10FN2O 
253.0772 
C7H6F 
109.0448 
C20H21FN3O 
338.1663 
STD 
Uni. of 
Athens 
WFTS 
C15H10FN2O 
253.0772 
C7H6F 
109.0448 
C20H21FN3O 
338.1663 
STD 
Labor 
Krone 
Thermo 2 
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Table 4.15 | Example from other SCs: 5-fluoro PY-PICA. 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF   
F2mass 
F3MF 
F3mass 
Origin LAB Method 
5-fluoro PY-
PICA 
C18H23FN2O 303.1867 
C14H15FNO 
232.1132 
C5H8NO 
98.0600 
C4H7 
55.0542 
TRT CPH SCFP 
C14H15FNO 
232.1132 
C5H8NO 
98.0600 
C9H6NO 
144.0444 
R CPH WFTS 
C14H15FNO 
232.1132 
C5H8NO 
98.0600 
- R Aarhus Bruker 3 
PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions, TRT: Theoretical, R: RESPONSE, CPH: Copenhagen, SCFP: Synthetic 
Cannabinoid Fragment Prediction, WFTS: Waters Forensic Toxicology Screening. 
 
Based on this analysis, it might be inferred that the predicted fragmentation could be useful in determining 
and interpreting future analogues. The established strategy provides the reader with comprehensive analytical 
information by exploring a variety of chemical structures for synthetic cannabinoids. However, this approach 
is not always perfect, therefore in some occasions it will not be possible to define a proper methodology, since 
the core skeleton might be slightly different. In other words, the inclusion of novel core sections, halogens in 
the tail sections, modification of functional groups in the linkers as well as linked groups may contribute to a 
completely distinct structure. According to the examples given for each sub-group, it is possible to verify that 
the first and second product ions match between laboratories, however this does not always apply to the third 
one, which commonly presents odd values. Nevertheless, we could conclude that the first ion might be of 
paramount importance for distinguishing the type of SCs and the remaining fragment ions conduce to addi-
tional information concerning the chemical composition of a certain compound within this drug class. In ad-
dition, it is worth noting that the ion values generated from the N-hetero rings may suggest the kind of core 
(i.e. indole or indazole). In this way, odd values result in substances comprising an indazole, whereas even 
ones originate substances containing an indole 146. In light of above, the strategy is not always feasible due to 
chemical modifications that may take place. JWH-175 (Figure 1.3b), which belongs to SCs with a naphthalene 
ring, is an example of this, the replacement of the usual linkers by a methylene group does not comply with 
the prior fragmentation principle.  
At this stage, the database comprised 1758 entries (Figure 4.17a). Owing to the number of multiple entries 
for the same substance, the previous estimative was considered with reference to compounds available on the 
database in March 2019. After downloading the database into an excel file, it was possible to notice the pres-
ence of 1251 compounds: 9 aminoindanes, 25 arylalkylamines, 20 arylcyclohexylamines, 41 benzodiazepines, 
433 cannabinoids, 158 cathinones, 77 indolalkylamines, 131 opioids, 176 phenethylamines, 28 piperazine deri-
vates, 27 piperidines & pyrrolidines, 20 plants & extracts and 106 unknown (Figure 4.17b). In comparison 
with the initial data (Figure 4.2), it might be concluded that the increase of entries is not considerable; however, 
we should take into account the quantity of compounds present on the database instead. Thus, 156 novel sub-
stances were additional included, contributing with significant theoretical information, more especifically in 
terms of fragment ions.    
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Figure 4.17  | HighResNPS database in March 2019: (a) number of entries and (b) number of compounds per drug class. 
 
According to the reported data, we have witnessed an evolution of the database concerning fragmentation. 
At that point, 775 NPS contained fragment ions while 476 were still absent. However, it is important to under-
stand how well these fragments match between laboratories/users. In this way, with the support of pivot tables 
this study was carry out. We realised that: 
▪ 273 compounds comprising fragments were reported by more than one laboratory. Of this, 99.6% 
(n=272) shared at least one fragment; 
▪ from 1501 fragments, 1004 were distinct fragments recorded by 273 compounds. 60% (n=603) of 
them were from more than one laboratory. 
Throughout the database, it is possible to notice the presence of 349 isomer groups. In other words, com-
pounds comprising an identical molecular formula, nevertheless a distinct chemical structure. Of note, posi-
tional isomers (i.e. ortho-, meta- and para-) are the more evident, which are characterised by different groups 
at the same carbon skeleton. For these cases, it might be challenging to identify the correct structure due to 
similarities in their fragment ions. The following examples: 2-fluoroamphetamine/3-fluoroamphetamine/4-
fluoroamphetamine (Table 4.16) and 2-APB/4-APB/5-APB/6-APB (Table 4.17), represent some NPS that 
cannot be easily distinguished. The three product ions available on the database for the previous substances 
are not enough to contribute for a proper interpretation, which means that we are not able to determine the 
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position of any of the substituents, since they can be present in more than one place in the considered mole-
cules. For the given examples, we have noticed in fact, that they comprehend equal values for the fragment 
ions. Therefore, it might be difficult to define the position of the substituents, since the fragmentation pattern 
is identical.  
Table 4.16 | Example 1: 2-fluoroamphetamine, 3-fluoroamphetamine and 4-fluoroamphetamine (phenethylamines). 
 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
2-fluoroamphetamine C9H12FN 154.1026 
C7H6F 
109.0448 
C9H10F 
137.0761 
C5H4F 
83.0292 
3-fluoroamphetamine C9H12FN 154.1026 
C7H6F 
109.0448 
C9H10F 
137.0761 
C5H4F 
83.0292 
4-fluoroamphetamine C9H12FN 154.1026 
C7H6F 
109.0448 
C9H10F 
137.0761 
C5H4F 
83.0292 
PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions. 
 
Table 4.17 | Example 2: 2-APB, 4-APB, 5-APB and 6-APB (arylalkylamines). 
 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
2-APB C11H13NO 176.1070 - - - 
4-APB C11H13NO 176.1070 - - - 
5-APB C11H13NO 176.1070 
C9H7O 
131.0491 
C11H11O 
159.0804 
C7H7 
91.0542 
6-APB C11H13NO 176.1070 
C9H7O 
131.0491 
C11H11O 
159.0804 
C7H7 
91.0542 
PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions. 
 
On the other hand, it is important to highlight that there are also compounds on the database that share the 
exact same mass, nonetheless it is possible to use the fragments to differentiate them, e.g. APP-PICA and 
CUMYL-THPINACA both synthetic cannabinoids with a parent mass of 378.2176 Da (Table 4.18). The first 
substance contains an indole (i.e. core), whereas the second one an indazole and the two comprise a carboxy-
amide linker attached to distinct moieties. In this way, the product ions allow us to distinguish these isomers, 
since the values associated to each of them are different. 
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Table 4.18 | APP-PICA and CUMYL-THPINACA: the exact same mass but different fragment ions. 
 
Compound PMF Pmass 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
APP-PICA C23H27N3O2 378.2176 
C14H16NO 
214.1226 
C9H6NO 
144.0444 
- 
CUMYL-THPINACA C23H27N3O2 378.2176 
C14H15N2O2 
243.1128 
C9H11 
119.0855 
C6H11O 
99.0804 
PMF: Parent Molecular Formula, Pmass: Parent mass, F1MF/F2MF/F3MF: Molecular formula of the three most abundant fragment ions, 
F1mass/F2mass/F3mass: Mass of the three most abundant fragment ions. 
 
After completing all these steps, the HighResNPS database can be further converted into an in-house library 
(i.e. a UNIFI library). To perform this process: 
1. HighResNPS is exported as a spreadsheet (excel file); 
2. The available entries are renamed to [name@item number], in order to enable the identification based 
on analytical information submitted by multiple laboratories. Thereof, the entries are further generated 
into .mol files, which depend on their IUPAC names.  
This procedure requires progamming skills, hence to facilitate the entire process it will be possible to find 
the required files on the database, allowing an easy access to the prior data to any user. In this way, they will 
be able to operate HighResNPS in their own LC-HRMS systems. However, at the moment the available files 
are exclusive to the UNIFI software. In this sense, the second part of this thesis will scrutinize a different 
approach to interpret the data without the need to import the database to the MS software. 
 
4.2 Part II – Screening for NPS in seizures 
In order to test the applicability of HighResNPS database in forensic analysis, 36 interesting samples (see 
appendix N) confiscated by the Danish authorities from 2015 to 2019 were processed using UHPLC-QTOF-
MS. However, only 14 samples will be described below in more detail, since the remaining ones resulted in 
identical outcomes or were not considered NPS, instead they made part of the so-called traditional drugs (e.g. 
heroin and MDMA). The mass spectral data for these 14 unknown compounds was acquired in positive mode 
and in data-independent acquisition (DIA). Of note, this acquisition mode enables the analysis of all precursor 
ions in the ion source, thereof are subjected to fragmentation, which is induced by a ramp of collision energy 
(CE) from 10 to 40 eV.  
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In light of above, the screening approach was based on the use of HighResNPS as an online mass spectral 
database, without the need to import the library. In order to carry out this study, a workflow composed by four 
steps was established: 
1. The total ion chromatogram (TIC): focus on the more intense peak; 
2. Precursor ion (M+H)+: search this value (i.e. at least select one decimal) on HighResNPS database to 
narrow down the possible candidates; 
3. Fragmentation profile: examine the fragments, comparing the experimental values with the ones avail-
able on HighResNPS. In case this is not possible, resort to mzCloudTM to obtain supplemental infor-
mation at this level. If none of these methods provide enough data, the reference standards might be 
purchased and/or nuclear magnetic resonance (NMR) spectroscopy techniques (especially for posi-
tional isomers) should be performed; 
4. Structure elucidation: a possible chemical structure of the compound is determined. 
 
4.2.1 Sample 1  
The Figure 4.18a illustrates a dominant chromatographic peak at 3.36 min. The presence of a sodium 
adduct (M+Na)+ at m/z 230.1146 demonstrates that the protonated molecule (M+H)+ may correspond to a m/z 
value 208.1332 (C21H17NO2) with a mass error (i.e. the difference between the experimental mass and the 
theoretical mass) of 0.0 mDa.  
 
 
 
This is possible due to the difference of 22 units between the two masses (Figure 4.18b). Based on the 
obtained precursor ion, the value can be searched on HighResNPS by typing the mass with two decimals 
“208.13”, in this way four compounds are highlighted: MBDB, MDDMA, MDEA and mexedrone (Figure 
4.19). In terms of drug classes, the former ones belong to the phenethylamines category and the last one is a 
Figure 4.18 | (a) LC-QTOF-MS total ion chromatogram (TIC), MSE collision spectra of the unknown 
sample 1 at (b) low energy (LE) and (c) high energy (HE). 
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representative of the cathinones group. Therefore, we can have a perception regarding the possible NPS classes 
that may be in this sample. However, the fragmentation is crucial to complete the analysis.  
 
Figure 4.19 | Possible candidates on HighResNPS with a precursor ion at m/z 208.1332. 
All the previous hints comprise fragment ions that can be compared with the ones observed experimentally 
(Table 4.19). The high energy (HE) mass spectrum (Figure 4.18c) provides information regarding three col-
lision-induced fragments, which are registered at m/z 158.0964, 176.1070 and 119.0491. In addition, if we 
look at the peak between the parent mass (m/z 208.1332) and fragment ion 2 (m/z 176.1070), we may observe 
the value 190.1225, which could suggest the existence of a carbonyl group owing to the loss of water (H2O, 
18 Da) 147. Based on this assumption and taking into account the listed compounds, it would enable us to select 
merely one. In this case, mexedrone, since it is the only substance that contains this functional group in its 
chemical structure. Thus, it is necessary to assure that the obtained product ions comply with the ones available 
on the HighResNPS database. In this online library, the following fragments are reported: 119.0491, 158.0964 
and176.1070 that completely agree with the ones in the spectrum. On the other hand, the remaining compounds 
correspond to ions that are not recorded (e.g. 105.0699 and 135.0440 (Table 4.19 and Appendix O)).  
Table 4.19 The product ions available on HighResNPS database, on mzCloudTM and in the literature for each candidate. 
Compound 
HighResNPS database 
mzCloudTM | CE= 40 
eV 
Literature 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Fragments 
MBDB 
C8H7O2 
135.0441 
C9H11 
119.0855 
C4H10N 
72.0808 
72.0808 
119.0855 
135.0441 
177.0910 
- 
MDDMA 
C10H11O2 
163.0754 
C8H9 
105.0699 
C8H7O2 
135.0441 
72.0808 
105.0699 
135.0441 
163.0754 
- 
MDEA 
C8H9 
105.0699 
C8H7O2 
135.0441 
C10H11O2 
163.0754 
- 
Mexedrone 
C11H12N 
158.0964 
C11H14NO 
176.1070 
C8H7O 
119.0491 
119.0491 
158.0964 
176.1070 
119.0491 148 
158.0964 148 
176.1070 148 
190.1226  148 
 
Herein, it is important to interpret the occurrence of the aforementioned fragments: 119.0491 (fragment a) 
results in a benzoyl with a methyl substituent (loss of 89 Da), 158.0964 is related to a loss of 50 Da, which 
may indicate the loss of water with a consecutive disruption of the bond attached to the methoxy group and 
lastly, a cyclisation; and 176.1070 (fragment b) represents a loss of methanol (CH3OH, 32 Da) (Figure 4.20). 
Furthermore, the results were confirmed on mzCloudTM; the product ions registered at 40 eV in positive mode 
and in the literature 148 were identical, proving that mexedrone is the compound present in this sample (Table 
4.19).  
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Figure 4.20  | Mexedrone: structure of its three fragments. 
4.2.2 Sample 2  
The Figure 4.21a shows a chromatographic peak at 5.48 min. In this case, it is observed that the protonated 
molecule (M+H)+ may correspond to a m/z value 338.2224 (C21H27N3O) with a mass error equal to -0.3 mDa 
and there is no evidence of sodium and potassium adducts (Figure 4.21b). According to the obtained precursor 
ion, the value can be quested on HighResNPS by adding the mass with one decimal “338.2”, thus one com-
pound is pointed up: ETH-LAD (Figure 4.22), which fits into the indolalkylamines class. Of note, this sub-
stance was reported two times by different laboratories. In terms of fragmentation, the HE spectrum (Figure 
4.21c) contributes with information at this level. Three collision-induced fragments were registered at m/z 
237.1380, 208.0988 and 309.1837.  
Figure 4.21 | (a) LC-QTOF-MS total ion chromatogram (TIC), MSE collision spectra of the unknown sample 2 at (b) low 
energy (LE) and (c) high energy (HE). 
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On HighResNPS, the following product ions are found: 208.0995, 237.1386, 281.1648 and 309.1837 (Ta-
ble 4.20). In this way, the two laboratories consider the same first ions (208.0995 and 237.1386); however, the 
last two fragments do not match (281.1648 and 309.1837), accordingly. 
Table 4.20 | The product ions available on HighResNPS database, on mzCloudTM and in the literature for ETH-LAD 149. 
Compound 
HighResNPS database mzCloudTM | CE= 40 eV 
Literature 
Laboratory 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Fragments 
ETH-LAD 
Denmark 
C16H17N2 
237.1386 
C19H23N3O 
309.1835 
C14H12N2 
208.0995 
- 
208.0757 149 
237.1386 149 
281.1648 149 
309.1836 149 Australia 
C18H21N2O 
281.1648 
C16H17N2 
237.1386 
C14H12N2 
208.0995 
 
In addition, the HE spectrum takes into account 237.1386, 208.0995 and 309.1837. In general, we could 
affirm that the chances to be ETH-LAD are high, since the users are in accord with two product ions (m/z 
208.0995 and m/z 237.1386) (Table 4.20).  
 
Figure 4.22 | Possible candidate on HighResNPS with a precursor ion at m/z 338.2227. 
Regarding the fragmentation pathway of this molecule, it is complex, therefore it will not be considered in 
here. Nevertheless, the article of Brandt et al.: Return of the lysergamides. Part III: Analytical characterization 
of N6-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P–ETH-LAD) 149 gives 
an overview concerning this subject. Based on the previous article, it is possible to conclude with certainty that 
ETH-LAD is the compound present in this sample, since the product ions are identical to the ones published 
(Table 4.20 and Figure 4.23). 
 
Figure 4.23 | ETH-LAD: structure of the fragments obtained from HighResNPS 149.  
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4.2.3 Sample 3 
In the chromatogram, it is observed a peak corresponding to 5.15 min (Figure 4.24a). The presence of a sodium 
adduct (M+Na)+ at m/z 393.1956 indicates that the protonated molecule (M+H)+ may correspond to a m/z value 
371.2137 (C22H27FN2O2) with a mass error of 0.8 mDa. This is due to a difference of 22 units between the two 
masses (Figure 4.24b).  
 
Figure 4.24 | (a) LC-QTOF-MS total ion chromatogram (TIC), MSE collision spectra of the unknown sample 3 at (b) low 
energy (LE) and (c) high energy (HE). 
Based on the obtained precursor ion, this value can be inspected on HighResNPS by typing the mass with 
two decimals “371.21”, in this sense three compounds are displayed: 2-fluoro methoxyacetylfentanyl (ocfen-
tanil), 3-fluoro methoxyacetylfentanyl and 4-fluoro methoxyacetylfentanyl (Figure 4.25), which are part of 
the opioids class, more specifically the fentanyls group. 
 
Figure 4.25 | Possible candidate on HighResNPS with a precursor ion at m/z 371.2129. 
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All the previous candidates contain fragment ions that can be compared with the ones observed experimen-
tally (Table 4.21). The HE spectrum (Figure 4.24c) provides information regarding two collision-induced 
fragments, which are registered at m/z 188.1441 and 105.0701. According to HighResNPS, the fragment ions 
associated to each hint are: 105.0699 and 188.1434 (for 2-fluoro methoxyacetylfentanyl), 105.0699, 188.1434 
and 250.1238 (for 3-fluoro methoxyacetylfentanyl) (Table 4.21). In terms of the characteristic product ions, 
188.1434 (fragment a) results from the cleavage of the piperidine ring and the amide moiety, whereas 
105.0699 (fragment b) derives from the previous ion and corresponds to a disruption between the alpha-
carbon and the piperidine ring (Figure 4.26) 143.  
 
Figure 4.26 | The three hints: structure of the main fragments. 
Regarding 4-fluoro methoxyacetylfentanyl no information on fragmentation is specified (Table 4.21). In 
this way, it is possible to notice that both compounds encompass an identical chemical structure (i.e. positional 
isomers), thus they are more likely to produce equivalent fragments as verified previously. For this reason, it 
might be challenging to determine which one it is present in the sample. In this case, HighResNPS alone is not 
enough to contribute to a reliable result, therefore we need to resort to other approaches such as, purchase the 
three reference standards and/or perform NMR analysis, in order to localize the position (-ortho, -meta or -
para) of the fluorine atom on the aniline ring. 
Table 4.21 | The product ions available on HighResNPS database, on mzCloudTM and in the literature for each candidate. 
Compound 
HighResNPS database mzCloudTM | CE= 40 eV 
Literature F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Fragments 
2-fluoro methoxya-
cetylfentanyl (Ocfen-
tanil) 
C13H18N 
188.1434 
C8H9 
105.0699 
- 
105.0699 
188.1434 
105.0699 150 
188.1434 150 
3-fluoro methoxya-
cetylfentanyl 
C13H18N 
188.1434 
C8H9 
105.0699 
C14H17FNO2 
250.1238 
105.0699 
188.1434 
- 
4-fluoro methoxya-
cetylfentanyl 
- - - - - 
 
4.2.4 Sample 4 
In Figure 4.27a, a chromatographic peak is observed at 5.28 min. In this case, the protonated molecule 
(M+H)+ corresponds to a m/z value 220.1700 (C20H25N3O) with a mass error of 0.4 mDa and likewise the 
previous sample, there is no evidence of sodium and potassium adducts (Figure 4.27). Based on the obtained 
precursor ion, this mass can be seek on HighResNPS by using the mass with one decimal “220.1”, in this way 
seven compounds are selected: 3-HO-PCE, 4-methyl-N,N-diethylcathinone, 4-methyl-N-ethyl-norpentedrone, 
NEiH, N-ethylhexedrone, NiPP and N-propylnorpentedrone (Figure 4.28). In terms of drug classes, the former 
one belongs to the arylcyclohexylamines category and the last ones are representatives of the cathinones group. 
Therefore, we can be aware regarding the possible NPS classes that might be in this sample. In this sense, the 
fragmentation plays an important role. Not all the previous hints comprise fragment ions that can be compared 
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with the ones observed experimentally. Merely 4-methyl-N-ethyl-norpentedrone and N-ethylhexedrone con-
tain fragments (Table 4.22). The HE spectrum (Figure 4.26c) encompasses information regarding three colli-
sion-induced fragments, which are registered at m/z 202.1593, 146.0963 and 91.0541. In addition, if we look 
at the peak recorded at 202.1591 (low energy (LE) mass spectrum), it might indicate the presence of a carbonyl 
group owing to the loss of water (H2O, 18 Da), which can be formed when a proton is attached to the oxygen 
atom 147. Based on this premise and taking into account the listed compounds, it is possible to exclude 3-HO-
PCE, since the remaining substances contain this functional group in their chemical structures. 
 
 
Hence, it is necessary to guarantee that the obtained product ions comply with any of the compounds avail-
able on HighResNPS. It is important to notice that 4-methyl-N,N-diethylcathinone, NEiH, NiPP and N-
propylnorpentedrone do not comprise fragments, in this way, a literature search might be essential to find 
information on fragmentation patterns that could facilitate the analysis process.    
 
Figure 4.27 | (a) LC-QTOF-MS total ion chromatogram (TIC), MSE collision spectra of the unknown sample 4 at (b) low 
energy (LE) and (c) high energy (HE). 
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Figure 4.28 | Possible candidates on HighResNPS with a precursor ion at m/z 220.1696. 
In the library, it is reported the following fragments: 105.0699, 144.0808 and 159.1042 (for 4-methyl-N-
ethyl-norpentedrone) and 91.0542, 130.0651, 146.0964 and 202.1590 (for N-ethylhexedrone) (Table 4.22). 
The latter compound contains more than one ion, since two laboratories included information on fragmenta-
tion.  
Table 4.22 | The product ions available on HighResNPS database, on mzCloudTM and in the literature for each candidate. 
Compound Laboratory 
HighResNPS database 
mzCloudTM | CE= 40 
eV 
Literature 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Fragments 
3-HO-PCE Denmark - - - - - 
4-methyl-N,N-dieth-
ylcathinone 
USA 
C9H11 
119.0855 
C6H14N 
100.1121 
C10H11O 
147.0804 
- - 
4-methyl-N-ethyl-nor-
pentedrone 
Finland 
C11H13N 
159.1042 
C10H10N 
144.0808 
C8H9 
105.0699 
- 
105.0699 151 
160.1121 151 
175.1117 151 
202.1590 151 
NEiH Denmark - - - - - 
N-ethylhexedrone 
Denmark 
C7H7 
91.0542 
C10H12N 
146.0964 
C14H20N 
202.1590 
91.0542 
146.0964 
202.1590 
91.0542 152 
146.0964 152 
202.1590 152 Australia 
C14H20N 
202.1590 
C10H12N 
146.0964 
C9H8N 
130.0651 
NiPP Denmark - - - - - 
N-propylnorpentedrone Denmark - - - - - 
N/A: not applicable 
 
According to the data, it might be assumed that N-ethylhexedrone is in the sample, which means that the 
fragments match accordingly (Figure 4.29). However, this is not the case of 4-methyl-N,N-diethylcathinone 
and 4-methyl-N-ethyl-norpentedrone, none of their product ions correspond to the ones acquired. For NEiH, 
NiPP and N-propylnorpentedrone, the fragmentation was predicted based on scientific articles 151,153 (Appendix 
P). Only one product ion (m/z 202.1590) is shared with N-ethylhexedrone and corresponds to the ones in the 
HE spectrum. Furthermore, the results were confirmed on mzCloudTM; the product ions registered at 40 eV in 
positive mode and in the literature 152 were identical to N-ethylhexedrone (Table 4.22), proving that it is the 
compound present in this sample.  
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Figure 4.29 | N-ethylhexedrone: structure of its three fragments. 
 
4.2.5 Sample 5  
The Figure 4.30a illustrates a chromatographic peak at 6.54 min. The protonated molecule (M+H)+ may 
correspond to a m/z value 375.2065 (C24H26N2O2) with a mass error of -0.2 mDa and no sodium and potassium 
adducts are observed (Figure 4.30b). Based on the obtained precursor ion, the value can be searched on 
HighResNPS by typing the mass with three decimals “375.206”, in this way it is highlighted one compound: 
furanyl fentantyl (Figure 4.31), which fits into the opioids class (i.e. fentanyls group).   
 
Of note, this substance was reported four times by different laboratories (Table 4.23). In terms of fragmen-
tation, the HE spectrum (Figure 4.30c) contributes with information at this level. Three collision-induced 
fragments were registered at m/z 188.1433, 105.0697 and 146.0961. 
Figure 4.30 | (a) LC-QTOF-MS total ion chromatogram (TIC), MSE collision spectra of the unknown sample 5 at (b) low 
energy (LE) and (c) high energy (HE). 
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Figure 4.31 | Possible candidate on HighResNPS with a precursor ion at m/z 375.2067. 
On HighResNPS, the following product ions are found: 105.0699, 146.0964 and 188.1434. In this way, the 
laboratories consider the same first ions (105.0699 and 188.1434); however, not all reported the last fragment 
(146.0964) (Table 4.23). 
Table 4.23 The product ions available on HighResNPS database, on mzCloudTM and in the literature for furanyl fentanyl 
143. 
Compound Laboratory 
HighResNPS database 
mzCloudTM | CE= 40 
eV 
Literature 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Fragments 
Furanyl fentanyl 
Australia 
C13H18N 
188.1434 
C8H9 
105.0699 
C10H12N 
146.0964 
105.0699 
146.0964 
188.1434 
 
105.0699 143 
188.1434 143 
 
Denmark 
C13H18N 
188.1434 
- - 
Denmark 
C13H18N 
188.1434 
- - 
Denmark 
C13H18N 
188.1434 
C8H9 
105.0699 
- 
 
In terms of the fragment ions, 188.1434 (fragment a) results from the cleavage of the piperidine ring and 
the amide moiety, 105.0699 (fragment b) derives from the previous ion and corresponds to a disruption be-
tween the alpha-carbon and the piperidine ring and lastly, 146.0964 is due to degradation of the piperidine 
(Figure 4.32) 143.  
 
Figure 4.32 | Furanyl fentanyl: structure of the three fragments. 
Furthermore, the result was confirmed on mzCloudTM; the product ions registered at 40 eV in positive mode 
and in literature 143 were identical (Table 4.23), proving that furanyl fentanyl is the compound present in this 
sample.  
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4.2.6 Sample 6  
In Figure 4.33a, a predominant chromatographic peak is observed at 11.54 min. The presence of a sodium 
adduct (M+Na)+ at m/z 399.2050 and a potassium adduct (M+K)+ at m/z 415.1788 demonstrates that the pro-
tonated molecule (M+H)+ may correspond to a m/z value 377.2232 (C21H29FN2O3) with a mass error of -0.3 
mDa. This is possible due to the difference of 22 and 38 units between the parent mass and adducts. In addition, 
in-source fragments are also evident in the LE spectrum (Figure 4.33b). 
 
Figure 4.33 | (a) LC-QTOF-MS total ion chromatogram (TIC), MSE collision spectra of the unknown sample 6 at (b) low 
energy (LE) and (c) high energy (HE). 
Based on the obtained precursor ion, the value can be searched on HighResNPS by typing the mass with 
two decimals “377.22”, in this way one compound is pointed up: 5F-MDMB-PICA (Figure 4.34), which fits 
into the cannabinoids class.  
 
Figure 4.34 | Possible candidate on HighResNPS with a precursor ion at m/z 377.2235. 
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Of note, this substance was reported three times by different laboratories (Table 4.24). In terms of frag-
mentation, the HE spectrum (Figure 4.34c) contributes with information at this level. Two collision-induced 
fragments were registered at m/z: 232.1129 and 144.0442. On HighResNPS, the following product ions are 
found: 144.0444 and 232.1132. In this way, the laboratories consider the same ions (Table 4.24).  
Table 4.24 | The product ions available on HighResNPS database, on mzCloudTM and in the literature for 5F-MDMB-
PICA 154. 
Compound Laboratory 
HighResNPS database mzCloudTM | CE= 40 eV 
Literature F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Fragments 
5F-MDMB-PICA 
Australia 
C14H15FNO 
232.1132 
C9H6NO 
144.0444 
- 
144.0444 
232.1132 
144.0444 154 
232.1132 154 
Denmark 
C14H15FNO 
232.1132 
C9H6NO 
144.0444 
- 
Denmark 
C14H15FNO 
232.1132 
C9H6NO 
144.0444 
- 
 
In terms of fragmentation, 232.1132 (fragment a) results from the core with a carbonyl group and the tail 
section, whereas 144.0444 (fragment b) derives from the previous ion and corresponds to a disruption of the 
core from the tail section (Figure 4.35) 44.  
 
Figure 4.35 | 5F-MDMB-PICA: structure of the two fragments. 
 
4.2.7 Sample 7  
The Figure 4.36a illustrates a chromatogram. In this specific situation, an impurity is detected at 11.65 
min, which is associated to the most intense peak. Hence, it was taken into account the second abundant at 
8.73 min. The presence of a sodium adduct (M+Na)+ at m/z 351.0438 and a potassium adduct (M+K)+ at m/z 
367.0178 demonstrates that the protonated molecule (M+H)+ may correspond to a m/z value 329.0620 
(C16H13ClN4S) with a mass error of -0.2 mDa (Figure 4.36b).  
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Based on the obtained precursor ion, the value can be checked on HighResNPS by typing the mass with 
one decimal “329.0”, in this way one compound is displayed: metizolam (Figure 4.37), which fits into the 
benzodiazepines class. 
 
Figure 4.37 | Possible candidate on HighResNPS with a precursor ion at m/z 329.0622. 
Of note, this substance was reported two times by different laboratories. The following product ions are 
identified: 275.0404 and 300.0231 (Table 4.25). According to the HE spectrum (Figure 4.36c), two collision-
induced fragments were registered at m/z: 275.0401 and 300.0227. It was observed that both match with the 
ones submitted in the library.  
 
 
Figure 4.36 | (a) LC-QTOF-MS total ion chromatogram (TIC), MSE collision spectra of the unknown sample 7 at (b) low 
energy (LE) and (c) high energy (HE). 
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Table 4.25 | The product ions available on HighResNPS database, on mzCloudTM and in the literature for metizolam. 
Compound Laboratory 
HighResNPS database 
mzCloudTM | CE= 40 
eV 
Literature 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Fragments 
Metizolam 
Australia 
C14H12ClN2S 
275.0404 
C14H9ClN4S 
300.0231 
- 
- - 
Denmark 
C14H12ClN2S 
275.0404 
C14H9ClN4S 
300.0231 
- 
 
In terms of fragmentation, 275.0404 corresponds to a loss of 54 Da and 300.0231 is associated to a loss of 
-CH2CH3 (29 Da) 155 (Figure 4.38).  
 
Figure 4.38 | Metizolam: structure of the two fragments. 
Furthermore, mzCloudTM does not comprise this substance on its list. However, it is possible to conclude 
that metizolam might be present in this sample. In order to make sure, the reference standard may be purchased.  
 
4.2.8 Sample 8  
The Figure 4.39a shows a chromatographic peak at 11.68 min. The presence of a sodium adduct (M+Na)+ 
at m/z 400.2005 and a potassium adduct (M+K)+ at m/z 416.1743 demonstrates that the protonated molecule 
(M+H)+ may correspond to a m/z value 378.2185 (C20H28FN3O3) with a mass error of -0.2 mDa. This is possible 
due to the difference of 22 and 38 units between the parent mass and respective sodium and potassium adducts 
(Figure 4.39b). 
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Figure 4.39 | (a) LC-QTOF-MS total ion chromatogram (TIC), MSE collision spectra of the unknown sample 8 at (b) low 
energy (LE) and (c) high energy (HE). 
Based on the obtained precursor ion, the value can be browsed on HighResNPS by typing the mass with 
three decimals “378.218”, therefore eight compounds are underlined: 2-fluoro ADB, 3-fluoro ADB, 4-fluoro 
ADB, 5-fluoro ADB, 5-fluoro AEB, 5-fluoro MDMB-PINACA, 5F-MDMB-P4AICA and 5F-MBMB-
P7AICA (Figure 4.40), which belong to the cannabinoids category. Some of the previous hints comprise frag-
ment ions on HighResNPS database that can be compared with the ones observed experimentally.  
 
Figure 4.40 | Possible candidates on HighResNPS with a precursor ion at m/z 378.2187. 
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Regarding 5F-MDMB-P4AICA and 5F-MBMB-P7AICA no information on fragmentation is defined. In 
this way, it is possible to notice that four compounds encompass an identical chemical structure (i.e. 2-, 3-, 4-
,5-fluoro ADB, positional isomers), thus they are more likely to produce equivalent fragments. In addition, 5-
fluoro AEB possesses a similar structure to 5-fluoro ADB, only differing in the moiety attached to the carbox-
yamide linker. When the product ions are not available, it is possible to predict them based on scientific articles 
44 (Appendix Q). The HE spectrum (Figure 4.39c) provides information regarding three collision-induced 
fragments, which are registered at m/z 233.1983, 318.1973 and 145.0394. The product ions were further com-
pared with the ones available on HighResNPS: 145.0396, 233.1085 and 318.1976, in some situations it is also 
reported 69.0699, 213.1022 and 231.1618 (Appendix R). This is observed since more than one laboratory 
submits the same compound and depending on the conditions, the fragments may suffer slight modifications 
(Appendix R). In this sense, it is not possible to solve this issue using only HighResNPS, other procedures 
should be carried out in order to discover the compound present in this sample. Thus, mzCloudTM might assist 
in the interpretation, the reference standards of each substance might be purchased and/or NMR analysis may 
contribute to obtain a reliable result. Based on mzCloudTM, it is possible to rule out one compound from the 
list (5-fluoro AEB), since it generates a product ion with a m/z 304.1820 (Appendix R), which is not in agree-
ment with the ones recorded in the HE spectrum. Nevertheless, it is important to notice that it contains two 
additional fragments (m/z 145.0396 and m/z 233.1085) that are identical to the other substances.  
 
4.2.9 Sample 9 
In the Figure 4.41a, a chromatographic peak is shown at 8.20 min. The presence of a sodium adduct 
(M+H)+ at m/z 349.0626 proves that the protonated molecule (M+H)+ may correspond to a m/z value 327.0811 
(C17H12ClFN4) with a mass error of 0.4 mDa.This is possible owing to the difference of 22 units between the 
masses (Figure 4.41b). 
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Figure 4.41 | (a) LC-QTOF-MS total ion chromatogram (TIC), MSE collision spectra of the unknown sample 9 at (b) low 
energy (LE) and (c) high energy (HE). 
Based on the obtained precursor ion, this value can be queried on HighResNPS by typing the mass with 
two decimals“327.08”, in this way only one compound is highlighted: flualprazolam, which makes part of the 
benzodiazepines class (Figure 4.42).  
 
Figure 4.42 | Possible candidate on HighResNPS with a precursor ion at m/z 327.0807. 
This substance was submitted two times by different laboratories. In terms of fragmentation, the HE 
spectrum (Figure 4.41c) gives an overview of the two collision-induced fragments, which were registered at 
m/z 299.0624 and 292.1121. On HighResNPS, the following product ions are observed: 292.1119 and 
299.0620, which are consistent with the ones obtained experimentally (Table 4.26). Therefore, we could 
conclude that this benzodiazepine might be present in the sample.  
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Table 4.26 | The product ions available on HighResNPS database, on mzCloudTM and in the literature for flualprazolam. 
Compound Laboratory 
HighResNPS database 
mzCloudTM | CE= 40 
eV 
Literature 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Fragments 
Flualprazolam 
Denmark 
C17H13FN4 
292.1119 
- - 
- - 
Denmark 
C17H13FN4 
292.1119 
C16H11ClFN3 
299.0620 
- 
 
According to the fragments, it is possible to notice that 299.0620 is associated to a loss of CH2N radical (28 
Da), however its chemical structure is not clear (a suggestion is presented), whereas 292.1119 corresponds to 
a loss of Cl radical (35 Da) 155 (Figure 4.43).  
 
Figure 4.43 | Flualprazolam: structure of the two fragments. 
 
4.2.10 Sample 10 
The Figure 4.44a depicts an abundant chromatographic peak at 8.44 min. In this case, there is no evidence 
of sodium and potassium adducts and the protonated molecule (M+H)+ corresponds to a m/z value 364.9690 
(C15H10BrClN2O2) with a mass error equal to 0.2660 mDa (Figure 4.44b). The obtained precursor ion can be 
further checked on HighResNPS by typing the mass with two decimals “364.96”, in this way two compounds 
are revealed: 3-hydroxyphenazepam and phenazepam 4-oxide (Figure 4.45), both belonging to the benzodi-
azepines class. Regarding the latter substance no information on fragmentation is reported. However, it is 
possible to predict its fragmentation based on scientific articles 156 (Appendix S). 
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Figure 4.44 | (a) LC-QTOF-MS total ion chromatogram (TIC), MSE collision spectra of the unknown sample 10 at (b) low 
energy (LE) and (c) high energy (HE). 
Therefore, the three induced-collision fragments (318.9633, 346.9586 and 273.0024) in the HE spectrum 
(Figure 4.44c) will be compared with the data available for 3-hydroxyphenezepam by two different laborato-
ries, which are identical: 273.0022, 318.9632 and 346.9581 (Table 4.27). Hence, we might conclude that 3-
hydroxy-phenazepam is the compound present in this sample (Appendix S). 
 
Figure 4.45 | Possible candidates on HighResNPS with a precursor ion at m/z 364.9687. 
Nevertheless, in order to guarantee a proper answer, the two reference standards should be purchased. 
Table 4.27 | The product ions available on HighResNPS database, on mzCloudTM and in the literature for each candidate. 
Compound Laboratory 
HighResNPS database mzCloudTM | CE= 40 eV 
Litera-
ture 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Fragments 
3-Hydroxy-
phenazepam 
Denmark 
C14H9BrClN2 
318.9632 
C15H9BrClN2O 
346.9581 
C13H10BrN2 
273.0022 
- - 
Greece 
C14H9BrClN2 
318.9632 
C15H9BrClN2O 
346.9581 
C13H10BrN2 
273.0022 
Phenazepam 4-oxide Denmark - - - - - 
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4.2.11 Samples 11 and 12  
The chromatograms illustrate a peak at 4.17 min (sample 11) and 6.85 min (sample 12) (Figure 4.46a). 
The protonated molecule (M+H)+ corresponds to a m/z value 260.2010 (C17H25NO) with a mass error of 0.1 
mDa (sample 11) and 260.2015 (C17H25NO) with a mass error equal to 0.6 mDa (sample 12). For both sam-
ples, there is no indication of sodium and potassium adducts (Figure 4.46b).  
 
Figure 4.46 | (a) LC-QTOF-MS total ion chromatogram (TIC), MSE collision spectra of the unknown samples 11 and 12 
at (b) low energy (LE) and (c) high energy (HE). 
Based on the obtained precursor ion, the value can be searched on HighResNPS by typing the mass with 
one decimal “260.2”, therefore three compounds are highlighted: 3-HO-PCP, MPHP and PV8 (Figure 4.47).  
 
Figure 4.47 | Possible candidates on HighResNPS with a precursor ion at m/z 260.2009. 
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In terms of drug classes, the former one belongs to the arylcyclohexylamines category and the last ones are 
representatives of the cathinones group. Therefore, we can have an insight into the possible NPS classes that 
may be in this sample. However, the fragmentation is decisive to complete the analysis. All the previous hints 
comprise fragment ions that can be compared with the ones observed experimentally. For sample 11, the HE 
spectrum (Figure 4.46c) provides information regarding three collision-induced fragments, which are regis-
tered at m/z 107.0495, 175.1119 and 86.0967. In addition, if we look out there is no peak that could suggest 
the existence of a carbonyl group owing to the loss of water (H2O, 18 Da) 147. Based on this assumption and 
taking into account the listed compounds, it would enable us to select merely one: 3-HO-PCP. Thus, it is 
necessary to assure that the obtained product ions comply with the ones available on the HighResNPS database. 
On the library, it is reported the following fragments: 86.0964, 107.0491 and 175.1117, which correspond with 
the ones acquired (Table 4.28). None of the fragments of the remaining two substances are compatible, a 
reason of exclusion (Appendix T). Regarding the fragment ions, it is possible to notice that 107.0491 is formed 
by the dissociation of the aryl moiety with the cyclohexyl unit, 175.1117 corresponds to the bond break be-
tween the cyclohexyl unit and the piperidine ring and the last one, 86.0964 is the result of the previous cleav-
age, giving rise to a piperidium (Figure 4.48).  
 
Figure 4.48 | 3-HO-PCP: structure of the three fragments. 
For sample 12, the HE spectrum (Figure 4.46c) provides information regarding three collision-induced 
fragments, which are registered at m/z 105.0704, 140.1438 and 189.1278. In the library, the following frag-
ments are reported for each substance: 107.0491, 86.0964 and 175.1117 (3-HO-PCP), 105.0699, 189.1274 and 
140.1434 (MPHP) and 91.0542, 154.1590 and 189.1274 (PV8). According to the previous information, it is 
possible to notice that MPHP exhibits the exact same product ions, the fragments of PV8 only correspond to 
one peak (m/z 189.1278), while 3-HO-PCP does not report any. Therefore, 3-HO-PCP may be ruled out. Con-
cerning the two remaining compounds, their fragments can be confirmed on mzCloudTM applying a collision 
energy 40 eV and in positive mode. Taking into account the fragmentation profile, it is observed that MPHP 
demonstrates akin results (m/z 105.0699 represents the base peak), whereas PV8 considers m/z 91.0542 the 
most intense peak and none of the aforementioned fragments are recorded. In this way, it might be inferred 
that MPHP is the unknown compound (Appendix T).  
Table 4.28 | The product ions available on HighResNPS database, on mzCloudTM and in the literature for each candidate. 
Compound 
HighResNPS database 
mzCloudTM | CE= 40 
eV 
Literature 
F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Fragments 
3-HO-PCP 
C7H7O 
107.0491 
C5H12N 
86.0964 
C12H15O 
175.1117 
- - 
MPHP 
C8H9 
105.0699 
C13H17O 
189.1274 
C9H18N 
140.1434 
105.0699 
140.1434 
189.1274 
105.0699 157 
140.1434 157 
189.1274 157 
PV8 
C7H7 
91.0542 
C10H20N 
154.1590 
C13H17O 
189.1274 
91.0542 
154.1590 
189.1274 
91.0591 157 
154.1590 157 
189.1274 157 
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4.2.12 Sample 13 
The Figure 4.49a represents an abundant chromatographic peak at 3.30 min. The presence of an in-source 
fragment (m/z 109.0452) demonstrates that the protonated molecule (M+H)+ corresponds to a m/z value 
182.1345 (C11H16FN) with a mass error of 0.6 mDa and there is no evidence of sodium and potassium adducts 
(Figure 4.49b).  
 
Figure 4.49 | (a) LC-QTOF-MS total ion chromatogram (TIC), MSE collision spectra of the unknown sample 13 at (b) low 
energy (LE) and (c) high energy (HE). 
The precursor ion can be investigated on HighResNPS by typing the mass with two decimals“182.13”, in 
this way two compounds are pointed up: 2-fluoroethamphetamine (2-FEA) and 3-fluoroethamphetamine (3-
FEA) (Figure 4.50), both phenethylamines. Of note, only 3-FEA comprises information on fragments, which 
are registered at m/z 109.0448 and 137.0761 (Table 4.29). Comparing these values with the ones obtained in 
the HE spectrum (Figure 4.49c), it is possible to notice the existence of two induced-collision fragments at 
m/z 109.0453 and 137.0764, which are in agreement with the ones recorded. 
 
Figure 4.50 | Possible candidates on HighResNPS with a precursor ion at m/z 182.1339. 
However, we are not able to provide a proper result, since both substances are positional isomers, which 
makes their distinction challenging  (Figure 4.51) 110.  
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Figure 4.51 | The two hints: structure of the main fragments based on scientific articles 110. 
In this way, it might be necessary to resort to other methods such as, purchase the two reference standards 
and/or carry out NMR experiments, in order to define the position of the fluorine atom on the aromatic ring.  
Table 4.29 | The product ions available on HighResNPS database, on mzCloudTM and in the literature for each candidate. 
Compound 
HighResNPS database mzCloudTM | CE= 40 eV 
Literature F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Fragments 
2-FEA - - - - - 
3-FEA 
C7H6F 
109.0448 
C9H10F 
137.0761 
- - - 
 
4.2.13 Sample 14 
In Figure 4.52a, it is illustrated a chromatographic peak at 3.07 min. The presence of in-source fragments 
at m/z 180.0578 and 145.0885 confirms that the protonated molecule (M+H)+ corresponds to a m/z value 
198.0685 (C10H12ClNO) with a mass error of 0.45 mDa (Figure 4.52b). 
 
Figure 4.52 | (a) LC-QTOF-MS total ion chromatogram (TIC), MSE collision spectra of the unknown sample 14 at (b) low 
energy (LE) and (c) high energy (HE). 
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The precursor ion can be further browsed on HighResNPS by typing the mass with one decimal “198.0”, 
therefore two compounds are found: 3-CMC and 4-CMC (Figure 4.53), both belonging to the cathinones class. 
 
Figure 4.53 | Possible candidates on HighResNPS with a precursor ion at m/z 198.0680. 
Of note, only 4-CMC comprises information on fragments, which are registered at m/z 145.0886, 180.0574, 
144.0808 and 139.0309. It is important to mention that this substance was reported by two laboratories that 
agree in the first two values, however the latter ones suffer some variations (Table 4.30).  
Table 4.30 | The product ions available on HighResNPS database, on mzCloudTM and in the literature for each candidate. 
Compound 
Labora-
tory 
HighResNPS database 
mzCloudTM | CE= 
40 eV Liter-
ature F1MF 
F1mass 
F2MF 
F2mass 
F3MF 
F3mass 
Fragments 
3-CMC Denmark 
C10H10N 
144.0808 
- - - - 
4-CMC 
Australia 
C10H11N 
145.0886 
C10H11ClN 
180.0574 
C10H10N 
144.0808 
- 
- 
Greece 
C10H11N 
145.0886 
C10H11ClN 
180.0574 
C8H8Cl 
139.0309 
- 
 
In addition, it is also observed a loss of water (18 Da), which results in a m/z 180.0578; this may confirm 
the existence of a carbonyl functional group 147. In comparison with the two induced-collision fragments at m/z 
145.0887 and 180.0578 (Figure 4.52c), it is possible to conclude that these two are consistent with the ones 
recorded. Nevertheless, 3-CMC and 4-CMC contain an identical chemical structure, thus it is difficult to sug-
gest which one is present in the sample due to their alike fragmentation (Figure 4.53).  
 
Figure 4.54 | The two hints: structure of the main fragments based on scientific articles 144. 
In this case, it would be recommended to find other alternatives that might help to identify the right sub-
stance such as, perform NMR experiments and/or buy the two reference standards to determine the position of 
the chlorine atom on the aromatic ring.  
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5 CONCLUSION AND FUTURE PERSPECTIVES 
The purpose of this dissertation was to improve and test a universal online library named HighResNPS for 
new psychoactive substances when reference standards are not readily available using UHPLC-QTOF-MS. 
The first part of this thesis consisted of ensuring that the database contained accurate information on the fol-
lowing parameters: drug class, IUPAC name and exact masses, including both precursor and fragment ions. In 
this way, the creation of two features allowed to successfully assigning 290 mass errors, to find some of the 
absent molecular formulae and to revise 61 systematic names. In addition, the InChIkey, which can be gener-
ated through the IUPAC name, is referred to as an important criterion for pinpoint compounds, since it is 
unique to a specific substance. The absence of this parameter may lead to a challenge, especially when dealing 
with isomers due to their similar fragmentation patterns, which makes their identification laborious. Further-
more, 333 entries reported by EMCDDA and RESPONSE libraries were excluded from the database, since 
they were not adding any valuable information. The previous entries comprised only exact mass, molecular 
formula, systematic name, InChIkey and drug class, which is termed as non-experimental data. However, the 
process was applied exclusively to compounds presenting more than one entry.  
In forensic analysis, fragmentation plays an important role in data analysis providing the scientist with 
structural information of a certain compound that might be helpful especially when reference standards are not 
available. In this sense, a combination of accurate-mass and fragmentation patterns allow the identification of 
substances present in the samples. Taking into account the NPS categories, it is essential to stress that not all 
the groups of compounds are easy to predict fragmentation owing to their structure complexity. The steady 
emergence of fentanyl analogues and synthetic cannabinoids on the drug market, and recently the occurrence 
of several acute intoxications and fatal cases lead us to predict the fragmentation of compounds within these 
two NPS classes. Therefore, two sub-libraries were created containing 51 and 215 compounds, respectively. 
The common fragmentation patterns were described for fentanyl analogues. It was verified that these com-
pounds cleave between the amide moiety bond and the piperidine ring. Further cleavages on the piperidine 
ring and in the C-N amide bond may also take place. This study came to prove that the first fragments coincide 
frequently with the ones reported among laboratories and, to a lesser extent, second and third product ions. 
Thus, the fragmentation pathways can be employed on future analogues, since it contributes to a general 
knowledge of the type of fentanyls we have at hand. In case of synthetic cannabinoids, this class of compounds 
is represented by a core, a tail section, a linker and a linked group, the variances among them may lead to 
different sub-groups. It was confirmed that the cleavage of the tested molecules mainly took place on the bond 
linking the carbon atom of the carbonyl group and the ring or the NH group attached to the ring. Furthermore, 
the predicted fragmentation might be useful in determining and interpreting future analogues. Based on the 
seven examples given for each sub-group, we concluded that the first product ion is imperative to distinguish 
the type of SCs and the remaining two fragment ions contribute with supplemental information on the chemical 
composition. It is worth noting that this approach is not always perfect due to the chemical modifications that 
may occur. For example, JWH-175 contains a methylene group as a linker, which does not comply with the 
fragmentation principles established.  
Regarding the database progress, we have noticed an evolution on the number of compounds and fragmen-
tation. In March 2019, it comprised 1251 compounds, meaning that 156 substances were included since the 
beginning of the validation process. Besides that, it is composed by 775 NPS containing product ions, whereas 
476 were still absent. In addition, 273 compounds with fragments were recorded by more than one laboratory 
and 99.6% shared at least one fragment. Throughout the database, it was possible to witness the presence of 
349 isomer groups. Of note, the positional isomers may pose a problem, since they differ merely in the position 
of a substituent and the fragmentation pattern is identical. On the other hand, some compounds may encompass 
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the exact same mass; nevertheless, it is possible to differentiate them thanks to a clearly difference in their 
fragment values, therefore promoting their identification.  
HighResNPS can be converted into an in-house library. In this thesis, a different approach is described to 
interpret the analytical information. It is important to highlight that it might be useful to import the database 
when dealing with complex samples (i.e. blood matrices); however, in the case of seizures, it is recommended 
to use it as an online mass spectral database, since it allows an easy access to the last updates, without the need 
to download a new version every time a novel entry/compound comes in.  
The second part of this thesis focused on the analysis of 14 unknown substances. The proposed workflow 
consisted of searching the precursor ion on the database using a mass with at least one decimal, which allowed 
to reduce the false positives. In addition, the fragmentation profile helped in ruling out some of the listed 
compounds. Thus, a possible chemical structure might be elucidated. Nonetheless, the latter step is not always 
attainable, especially when positional isomers come into play. In this sense, it might be necessary to resort to 
other methodologies such as, perform NMR analysis and/or purchase reference standards (i.e. comparing the 
Rt of all compounds), in order to determine the position of a certain substituent. Furthermore, a tentative iden-
tification and confirmation of the tested samples might be possible thanks to the use of mzCloudTM (i.e. spectra 
comparison) and search of scientific articles. Hence, HighResNPS may provide a preliminary identification 
concerning the NPS class of the analysed sample and increase the chances of finding the right compound. 
Finally, the success of the database relies on how active the users are. As a universal library, it is fundamental 
that the involved laboratories share their results, so that the analysis can be more accurate.  
In terms of future perspectives, it would be interesting to predict the retention time (Rt) for the current and 
future compounds and on a more advanced level, use software tools to envisage the fragmentation for each 
drug class available on the database.
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7 APPENDICES 
 
Appendix A | 58 novel compounds monitored in six drug websites. The green colour represents where the substances were 
found. 
Compound erowid.org Chem.eu 
NMS 
labs 
forendex 
EWS 
Forum 
drugs-fo-
rum.com 
Drug 
class 
Monitoring 
date 
Bromadol       ACH 25/10/2018 
MIPLA       I 25/10/2018 
4-ANPP       P&P 26/10/2018 
m-Methyl methoxyacetyl 
fentanyl 
      OPD 26/10/2018 
p-Methyl methoxyacetyl 
fentanyl 
      OPD 26/10/2018 
trans-3-Methyfentanyl       OPD 26/10/2018 
Delorazepam       BZD 26/10/2018 
1,3-Benzodioxol-
ylbutanamine (BDB) 
      PEA 26/10/2018 
4-Ethylamphetamine       PEA 26/10/2018 
4-Fluoro MDMB-PICA 
metabolite 7 
      CB 26/10/2018 
ADB-PINACA pentanoic 
acid metabolite 
      CB 26/10/2018 
MAB-CHMINACA meta-
bolite M2 
      CB 26/10/2018 
MAB-CHMINACA meta-
bolite M3 
      CB 26/10/2018 
MDMB-FUBINACA me-
tabolite M1 
      CB 26/10/2018 
AM2201 8-quinolinyl car-
boxyamide 
      CB 29/10/2018 
4-HO-MPT       I 29/10/2018 
N-Methylephedrine       PEA 29/10/2018 
2-Methylacetylfentanyl       OPD 29/10/2018 
4-HO-DMT       I 29/10/2018 
AMB-4en-PICA       CB 29/10/2018 
4-Fluoro-cyclopropyl-
benzylfentanyl 
      OPD 29/10/2018 
2-Fluoroethamphetamine; 
2-FEA 
      PEA 29/10/2018 
3,4-Methylenedioxy-U-
47700 
      OPD 29/10/2018 
3F-α-PVP       CAT 29/10/2018 
25E-NBOH       PEA 29/10/2018 
4-Desoxymescaline       PEA 01/11/2018 
Tapentadol       OPD 01/11/2018 
1,4-Butanediol       UNK 01/11/2018 
4-MeO-DMT       I 01/11/2018 
N,N-Dibutyltryptamine       I 01/11/2018 
Pyr-T (N,N-tetramethyle-
netryptamine) 
      I 01/11/2018 
Methylbutyltryptamine 
(MBT) 
      I 01/11/2018 
Ethylisopropyltryptamine 
(EiPT) 
      I 01/11/2018 
2CBFly-NBOMe 
(NBOMe-2C-B-FLY) 
      PEA 01/11/2018 
ACH: Arylcyclohexylamines, I: Indolalkylamines, P&P: Piperidines & pyrrolidines, OPD: Opioids, BZD: Benzodiazepines, PEA: 
Phenethylamines. 
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CB: Cannabinoids, CAT: Cathinones, UNK: Unknown, P&E: Plants & extracts, AIS: Aminoindanes.  
 
 
 
 
 
 
 
 
 
 
 
 
Compound erowid.org Chem.eu 
NMS 
labs 
 
forendex 
EWS 
Forum 
drugs-fo-
rum.com 
Drug 
class 
Monitoring 
date 
N-Ethyltrypta-
mine (NET) 
   
 
   I 01/11/2018 
CB-52        CB 01/11/2018 
CB-25        CB 01/11/2018 
BAY 38-7271        CB 01/11/2018 
Harmaline        P&E 01/11/2018 
AKB-N1        CB 01/11/2018 
6-Methyl-MDA        PEA 01/11/2018 
N-Methyltryptamine        I 01/11/2018 
2,5-Dimethoxy-4-
ethylamphetamine 
(DOET) 
   
 
   PEA 01/11/2018 
α-Ethyltryptamine        I 01/11/2018 
CP 55,244        CB 01/11/2018 
MMAI        AIS 01/11/2018 
4-HO-DALT        I 01/11/2018 
5-Methyl-MDA        PEA 01/11/2018 
4-HO-DBT        I 01/11/2018 
4-HO-MPT        I 01/11/2018 
4-HO-pyr-T        I 01/11/2018 
MDMAI        AIS 01/11/2018 
2C-T-21        PEA 01/11/2018 
Naloxegol        OPS 01/11/2018 
Bromazepam        BZP 01/11/2018 
Flunitrazepam        BZP 01/11/2018 
Eluxadoline        UNK 16/11/2018 
1B-LSD        I 16/11/2018 
Appendix A | 58 novel compounds monitored in six drug websites. The green colour represents where the substances 
were found (continued). 
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Appendix B | Masses corresponding to first, second and third fragments (on the right, at the centre and on the left, re-
spectively). The green colour represents the values to rectify and the red ones are not able to find. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Row Labels 
Count of 
ID 
91.0535 1 
109.0454 1 
121.0658 1 
150.0185 1 
152.0621 1 
162.1267 1 
165.0734 1 
179.0524 1 
181.1014 1 
197.1285 1 
202.1590 1 
203.1064 1 
208.1154 1 
216.1747 1 
243.1853 1 
245.0921 1 
255.1487 1 
264.1747 1 
269.0743 1 
308.0816 1 
309.1809 1 
Total 21 
Row Labels 
Count of 
ID 
55.0178 1 
85.0104 1 
88.0758 1 
115.0542 3 
142.1589 1 
147.1034 1 
152.0621 1 
154.1586 1 
165.0883 1 
168.1752 1 
169.1701 1 
175.1113 1 
189.1282 1 
194.0937 1 
224.1281 2 
230.0812 1 
244.0968 2 
272.1070 1 
280.0638 1 
295.0900 1 
312.9159 1 
326.1539 1 
340.1696 1 
Total 27 
Row Labels 
Count of 
ID 
67.0542 1 
87.0913 1 
101.0898 1 
115.0542 1 
121.0647 1 
128.1069 1 
131.0849 1 
158.1176 1 
161.0818 1 
176.0705 1 
176.0706 1 
189.1258 1 
195.0988 1 
214.9178 1 
221.1073 1 
221.1338 1 
231.1206 1 
236.1281 1 
239.1175 1 
242.1365 1 
298.1546 1 
324.1955 1 
Total 22 
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Appendix C | Fentanyl analogues used for fragmentation prediction. 
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Appendix D | Fentanyl analogues: common theoretical masses for fragments a, b, b2, c, c2 and d 143,144. 
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Appendix D | Fentanyl analogues: common theoretical masses for fragments a, b, b2, c, c2 and d (continued) 143,144. 
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Appendix E | Synthetic cannabinoids used for fragmentation prediction. 
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Appendix F | Common theoretical masses for SCs with adamantyl ring 
containing a carboxyamide or carbonyl functions. 
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Appendix G | Common theoretical masses for SCs containing a naphthalene ring and a car-
bonyl group.  
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Appendix H | Common theoretical masses for SCs containing a naphthalene ring and a carboxyl 
group.  
 
APPENDICES 
 
102 
 
 
 
 
 
 
Appendix I | Common theoretical masses for SCs containing a naphthalene ring and a carboxyamide 
group. 
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Appendix J | Common theoretical masses for SCs with TMCP moiety: fragment c. 
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Appendix K | Common theoretical masses for PINACA-SCs. 
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Appendix L | Common theoretical masses for FUBINACA-SCs. 
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Appendix M | Common theoretical masses for CHMINACA-SCs. 
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Appendix N | List of 36 unknown samples with their respective elemental compositions, precursor ions, fragments and a 
tentative identification of the substance present in the samples.  
Sample 
RT 
(min) 
Elemental com-
position 
Accurate mass 
Mass error 
(mDa) 
Tentative identification Precursor ion 
(M+H)+ 
Product 
ion 
1 3.36 
C21H17NO2 208.1332  0.0 
Mexedrone 
C8H7O 119.0490 -0.1 
C11H12N 158.0964 0.0 
C11H14NO 176.1069 -0.1 
2 5.48 
C21H27N3O 338.2224  -0.3 
ETH-LAD 
C14H12N2 208.0988 -0.7 
C16H17N2 237.1380 -0.6 
C19H23N3O 309.1837 0.1 
3 5.15 
C22H27FN2O2 371.2137  0.8 3-Fluro methoxy acetylfentanyl 
4-Fluoro acetylfentanyl 
Ocfentanil 
C8H9 105.0701 0.2 
C13H18N 188.1441 0.7 
4 5.28 
C20H25N3O 220.1696  0.4 
N-ethylhexedrone 
C7H7 91.0541 -0.1 
C10H12N 146.0963 -0.1 
C14H20N 202.1593 0.3 
5 6.54 
C24H26N2O2 375.2065  -0.2 
Furanyl fentanyl 
C8H9 105.0697 -0.2 
C10H12N 146.0961 -0.3 
C13H18N 188.1433 -0.1 
6 11.54 
C21H29FN2O3 377.2232  -0.3 
5F-MDMB-PICA C9H6NO 144.0442 -0.2 
C14H15FNO 232.1129 -0.3 
7 8.73 
C16H13ClN4S 329.0620  -0.2 
Metizolam C14H12ClN2S 275.0401 -0.3 
C14H9ClN4S 300.0227 -0.4 
8 11.68 
C20H28FN3O3 
378.2185 
 -0.2 
2-Fluoro ADB 
3-Fluoro ADB 
4-Fluoro ADB 
5-Fluoro ADB 
5F-MDMB-P4AICA 
5F-MDMB-P7AICA 
C8H5N2O 145.0394 -0.3 
C20H28FN3O3 233.1083 -0.2 
C13H14FN2O 318.1973 -0.3 
9 8.20 
C17H12ClFN4 327.0811  0.4 
Flualprazolam C17H12ClFN4 292.1121 0.2 
C17H12ClFN4 299.0624 0.4 
10 8.44 
C15H10BrClN2O2 364.9690  0.3 
3-Hydroxyphenazepam 
 
C13H10BrN2 273.0024 0.2 
C14H9BrClN2 318.9633 0.1 
C15H9BrClN2O 346.9586 0.5 
11 4.17 
C17H25NO 260.2010  0.1 
3-HO-PCP 
 
C5H12N 86.0967 0.3 
C7H7O 107.0495 0.4 
C12H15O 175.1119 0.2 
12 6.85 
C17H25NO 260.2015  0.6 
MPHP 
 
C8H9 105.0704 0.5 
C9H18N 140.1438 0.4 
C13H17O 189.1278 0.4 
13 3.30 
C11H16FN 182.1345  0.6 
2-FEA 
3-FEA 
C7H6F 109.0453 0.5 
C9H10F 137.0764 0.3 
14 3.07 
C10H12ClNO 198.0685  0.5 
3-CMC 
4-CMC 
C10H11N 145.0887 0.1 
C10H11ClN 180.0578 0.4 
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Appendix N | List of 36 unknown samples with their respective elemental compositions, precursor ions, fragments and a 
tentative identification of the substance present in the samples (continued). 
Sample 
RT 
(min) 
Elemental com-
position 
Accurate mass 
Mass error 
(mDa) 
Tentative identification Precursor ion 
(M+H)+ 
Product 
ion 
15 5.73 
C161H19N 226.1593  0.3 
Ephenidine 
C8H7O 103.0542 0.0 
C11H12N 181.1014 0.2 
C11H14NO 176.1069 -0.1 
16 6.15 
C16H22Cl2N2O 329.1182  0.0 
U-47700 
C7H3Cl2O 172.9556 0.1 
C8H8Cl2NO 203.9985 0.8 
C16H17N2 284.0612 0.9 
17 |5.40 
C20H25N3O 324.2065  -0.5 
Iso-LSD 
 
C14H10NO 208.0761 0.4 
C15H15N2 223.1224 -0.6 
C18H21N2O 281.1636 -1.2 
18 11.68 
C20H28FN3O3 
378.2185 
 -0.2 
2-Fluoro ADB 
3-Fluoro ADB 
4-Fluoro ADB 
5-Fluoro ADB 
5F-MDMB-P4AICA 
5F-MDMB-P7AICA 
C8H5N2O 145.0394 -0.3 
C20H28FN3O3 233.1083 -0.2 
C13H14FN2O 318.1973 -0.3 
19 8.20 
C17H12ClFN4 327.0811  0.4 
Flualprazolam C17H12ClFN4 292.1121 0.2 
C17H12ClFN4 299.0624 0.4 
20 6.93 
C17H12FN5O2 338.1049  0.2 
Flunitrazolam 
C16H11FN3 264.0936 0.5 
C17H13FN4 292.1117 -0.2 
C16H11FN4O2 300.0859 -0.1 
21 5.20 
C20H25N3O 220.1696  0.4 
N-ethylhexedrone 
C7H7 91.0541 -0.1 
C10H12N 146.0963 -0.1 
C14H20N 202.1593 0.3 
22 3.05 
C10H12ClNO 198.0685  0.5 
3-CMC 
4-CMC 
C10H11N 145.0887 0.1 
C10H11ClN 180.0578 0.4 
23 5.41 
C16H23NO 246.1860  0.8 
α-PiHP 
C7H7 91.0547 0.5 
C7H5O 105.0340 0.5 
C9H18N 140.1438 0.4 
24 8.15 
C17H12ClFN4 327.0811  0.4 
Flualprazolam C17H12ClFN4 292.1121 0.2 
C17H12ClFN4 299.0624 0.4 
25 3.29 
C11H16FN 182.1345  0.6 
2-FEA 
3-FEA 
C7H6F 109.0453 0.5 
C9H10F 137.0764 0.3 
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Sample 
RT 
(min) 
Elemental com-
position 
Accurate mass 
Mass error 
(mDa) 
Tentative identification Precursor ion 
(M+H)+ 
Product ion 
26 2.48 
C11H15NO2 194.1179  0.4 
MDMA 
C7H5O 105.0339 0.4 
C8H7O2 135.0445 0.4 
C10H11O2 163.0757 0.3 
27 6.93 
C17H12FN5O2 338.1049  0.2 
Flunitrazolam 
C16H11FN3 264.0936 0.5 
C17H13FN4 292.1117 -0.2 
C16H11FN4O2 300.0859 -0.1 
28 6.93 
C17H12FN5O2 338.1049  0.2 
Flunitrazolam 
C16H11FN3 264.0936 0.5 
C17H13FN4 292.1117 -0.2 
C16H11FN4O2 300.0859 -0.1 
C16H11FN3 264.0936 0.5 
29 4.02 
C21H23NO5 370.1650   
Heroin 
C14H11O2 211.0753 -0.1 
C17H18NO2 268.1331 -0.1 
C19H22NO4 328.1541 -0.2 
30 4.02 
C21H23NO5 370.1650   
Heroin 
C14H11O2 211.0753 -0.1 
C17H18NO2 268.1331 -0.1 
C19H22NO4 328.1541 -0.2 
31 4.02 
C21H23NO5 370.1650   
Heroin 
C14H11O2 211.0753 -0.1 
C17H18NO2 268.1331 -0.1 
C19H22NO4 328.1541 -0.2 
32 4.02 
C21H23NO5 370.1650   
Heroin 
 
C14H11O2 211.0753 -0.1 
C17H18NO2 268.1331 -0.1 
C19H22NO4 328.1541 -0.2 
33 4.02 
C21H23NO5 370.1650   
Heroin 
C14H11O2 211.0753 -0.1 
C17H18NO2 268.1331 -0.1 
C19H22NO4 328.1541 -0.2 
34 4.02 
C21H23NO5 370.1650   
Heroin C14H11O2 211.0753 -0.1 
C17H18NO2 268.1331 -0.1 
C19H22NO4 328.1541 -0.2 
35 4.17 
C17H25NO 260.2010  -0.1 
3-HO-PCP 
 
C5H12N 86.0967 0.3 
C7H7O 107.0495 0.4 
C12H15O 175.1119 0.2 
36 3.07 
C10H12ClNO 198.0685  0.5 
3-CMC 
4-CMC 
C10H11N 145.0887 0.1 
C10H11ClN 180.0578 0.4 
 
 
 
 
 
 
Appendix N | List of 36 unknown samples with their respective elemental compositions, precursor ions, fragments and 
a tentative identification of the substance present in the samples (continued). 
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Appendix O | Sample 1: theoretical fragments for MBDB, MDDMA and MDEA 110. 
 
 
Appendix P | Sample 4: product ions available on HighResNPS (A) and theoretical fragments for NEiH, NiPP and N-
propylnorpentedrone (B) 151,153. 
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Appendix Q | Sample 8: theoretical fragments for 5F-MDMB-P4AICA 44.  
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Appendix R | Sample 8: structure of product ions (A) and information on fragmentation available on HighResNPS (B) for 
2-fluoro ADB, 3-fluoro ADB, 4.fluoro ADB, 5-fluoro ADB and 5-fluoro AEB. 
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Appendix R | Sample 8: structure of product ions (A) and information on fragmentation available on HighResNPS (B) 
for 2-fluoro ADB, 3-fluoro ADB, 4.fluoro ADB, 5-fluoro ADB and 5-fluoro AEB (continued). 
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Appendix S | Sample 10: theoretical fragments for 3-hydroxyphenazepam and phenazepam 4-oxide 156. 
 
 
Appendix T | Samples 11 and 12: Theoretical fragments for MPHP and PV8 157. 
 
 
 
